詳細検索

詳細検索

お問い合わせ

ヒトオルガノイド市場:提供形態、種類、培養方法、由来、疾患領域、用途、エンドユーザー別 ― 2031年までの世界市場予測

ヒトオルガノイド市場:提供形態、種類、培養方法、由来、疾患領域、用途、エンドユーザー別 ― 2031年までの世界市場予測


Human Organoids Market by Offering, Type, Culture Type, Source, Disease Area, Application, End User - Global Forecast to 2031

世界のヒトオルガノイド市場は、2026年の0.29億米ドルから、2031年までに0.90億米ドルに達すると予測されており、年平均成長率(CAGR)は25.6%となる見込みです。 製薬企業や研究機関が、ヒト組織生物学の主要... もっと見る

 

 

出版社
MarketsandMarkets
マーケッツアンドマーケッツ
出版年月
2026年11月10日
電子版価格
US$4,950
シングルユーザーライセンス
ライセンス・価格情報/注文方法はこちら
納期
通常2営業日以内
ページ数
405
図表数
585
言語
英語

英語原文をAIを使って翻訳しています。


 

サマリー

世界のヒトオルガノイド市場は、2026年の0.29億米ドルから、2031年までに0.90億米ドルに達すると予測されており、年平均成長率(CAGR)は25.6%となる見込みです。 製薬企業や研究機関が、ヒト組織生物学の主要な特徴を再現するモデルを採用するにつれ、世界のヒトオルガノイド市場は予測期間中に拡大すると見込まれています。本調査では、医療および製薬用途向けの完成品オルガノイドモデル、モデル開発、ならびにオルガノイドを用いた試験サービスを対象としています。 別途販売される培地、試薬、消耗品、機器は対象外であり、化粧品、獣医、食品、農業、環境用途も対象外となる。FDAが2025年4月に発表したロードマップは、オルガノイドを用いた毒性試験を含む、検証済みの非動物試験法の評価を支持している。 疾患特異的なモデルやスケーラブルなスクリーニングへの需要は、サプライヤーにとってビジネスチャンスとなる。一方で、コスト、専門的なノウハウ、バッチ間のばらつき、組織の成熟度の不完全さなどが導入の障壁となり得るため、慎重な検証が必要となる。

すぐに使用でき、カスタマイズ可能なオルガノイドモデルは、ヒトに関連する研究システムへの活用を可能にします。
提供内容に基づき、この市場はオルガノイドモデルとサービスに区分される。モデルセグメントには、完成品として提供される即用型およびカスタマイズ可能なオルガノイドが含まれる。サービスには、モデルの開発やオルガノイドモデルを用いた試験などが含まれる。 モデルを購入した研究者は自施設の研究室で実験を行うことができる一方、外部委託サービスでは専門的な開発やスクリーニング機能を提供している。ダナハー傘下のMolecular Devices(米国)は、アッセイ対応のオルガノイドおよびカスタム培養拡大サービスを提供している。 メルクKGaA(ドイツ)傘下のHUB Organoids(オランダ)は、カスタムモデルの開発および創薬スクリーニングを提供している。モデルの品質、ドナーの特性、およびアッセイへの適合性は、製薬企業、研究機関、CRO/CRDMOにおける購入決定に影響を与える。

腸および大腸のオルガノイドモデルは、消化器系の研究やがん検診のニーズに応えるものです。
本調査では、モデルタイプに基づき、肝臓、腸・大腸、腎臓、膵臓、肺、心臓、およびその他のオルガノイドモデルを対象としています。その他のモデルには、脳、網膜、乳房、皮膚のオルガノイドが含まれます。 腸および大腸モデルにより、研究者は患者に関連するシステムにおいて、上皮機能、疾患メカニズム、および薬剤反応を調査することができる。Molecular Devices(米国)は、アッセイに即座に使用可能な大腸がんおよび腸オルガノイド株を提供しており、完成したモデルへの商業的なアクセスが可能であることを示している。 腎臓オルガノイドも腎疾患の研究を支援しており、Evotec(ドイツ)のiPS細胞由来腎臓オルガノイドの能力がその一例である。各モデルタイプに対する需要は、組織機能、対象となる疾患の範囲、および意図された実験エンドポイントへの適合性によって異なる。

予測期間中、オルガノイド研究サービスはアジア太平洋地域においてビジネスチャンスを拡大している。
対象地域は、北米、欧州、アジア太平洋、ラテンアメリカ、中東、およびアフリカです。アジア太平洋地域では、プロバイダー各社がヒトオルガノイドを用いた創薬サービスを拡大していることから、ビジネスチャンスが生まれています。 サムスン・バイオロジクス(韓国)は2025年6月に「サムスン・オルガノイド」を立ち上げ、患者由来の腫瘍オルガノイドスクリーニングを通じて、サービスを前臨床研究分野へと拡大した。ウーシー・アプテック(中国)は、ウーシー・バイオロジーを通じて、in vitroでの腫瘍学スクリーニング向けの異種移植片由来オルガノイドモデルを開発している。 こうした技術力は、疾患関連モデルや治療法評価の外部委託に対する需要を支えている。同地域における成長は、研究投資、患者由来試料へのアクセス、モデルの再現性、および特定の用途に向けたオルガノイド手法の検証にかかっている。

ヒトオルガノイドに関する調査の主な回答者カテゴリーは以下の通りです。
- 回答者別:オルガノイドモデルおよびサービスの供給側プロバイダー、ならびに製薬、バイオテクノロジー、生物医学研究機関における需要側のユーザー
- 企業タイプ別:多角的なライフサイエンス企業、CRO/CRDMO、オルガノイド専門開発企業、スタートアップ/中小企業
- 役職別:CXOおよび取締役、研究・事業マネージャー、科学者、その他の技術専門家
- 地域別:北米、欧州、アジア太平洋、ラテンアメリカ、中東、アフリカ

本調査の対象企業一覧
- サーモフィッシャーサイエンティフィック社
- ダナハー・コーポレーション
- メルクKGaA
- ユーロフィン・サイエンティフィック
- ウーシー・アプテック
- チャールズ・リバー・ラボラトリーズ
- ブルカー・コーポレーション
- ファーマロン
- エボテック
- ACROBiosystems
- サムスン・バイオロジクス
- その他の企業

調査対象分野
本レポートでは、ヒトオルガノイド市場を、提供内容、モデルタイプ、培養タイプ、由来、疾患領域、用途、エンドユーザー、および地域ごとに分類しています。モデルおよびサービスのエンドユーザーについては、個別に評価を行っています。 本調査では、過去データとして2023年~2024年、基準年として2025年、および2026年~2031年の予測を網羅している。また、成長要因、制約要因、機会、課題、価格設定、資金調達、技術的進歩、AIの応用、規制動向についても分析している。 競合分析には、企業プロファイル、売上高および市場シェア分析、企業評価マトリックス、提供範囲、戦略的展開が含まれます。市場売上高は、完成したヒトオルガノイドモデルおよびモデル開発・試験サービスに限定されます。一般的な培養用資材や機器は、市場推計の対象外となります。

本レポートを購入する主なメリット
本レポートは、既存のサプライヤーや新規参入企業が、完成品オルガノイドモデルおよび研究サービス全般にわたる収益機会を評価するのに役立ちます。また、モデルポートフォリオ、治療分野の重点、顧客層、および地理的拡大に関する意思決定を支援します。 サプライヤーの能力、購入基準、導入障壁に関する分析は、ステークホルダーが市場参入戦略や提携戦略を策定する上で役立ちます。また、本調査では、標準化、スケーラブルな生産、および検証済みの試験方法が、需要や競争上の位置づけにどのような影響を与えるかについても検証しています。

本レポートでは、以下のポイントについて洞察を提供しています:
- ヒト関連薬剤スクリーニング、患者由来疾患モデル、および動物実験に代わる検証済みの代替法に対する需要といった主要な推進要因、モデル開発コストや専門的なノウハウといった制約、スケーラブルなオルガノイドの供給、個別化医療の研究、 AIを活用したモデル標準化)、および課題(バッチ間のばらつき、組織の成熟度の限界、および施設間の再現性の問題)の分析。
- 製品開発/イノベーション:完成したオルガノイドモデル、モデル開発および試験サービス、自動化、AIを活用したオルガノイドワークフローに関する洞察。
- 市場開発:調査対象範囲に含まれる6つの地域および各国における、ヒトオルガノイドモデルおよびサービスの機会に関する評価。
- 市場の多様化:新興の疾患モデル、研究用途、満たされていない顧客ニーズ、資金調達、および地理的拡大の機会に関する分析。
- 競合評価:メルクKGaA(ドイツ)、ダナハー・コーポレーション(米国)、サムスン・バイオロジクス(韓国)、ウーシー・アプテック(中国)、エボテック(ドイツ)を含む各企業の市場での位置づけ、成長戦略、およびオルガノイド関連製品の提供状況に関する評価。



お問い合わせ

お問合せ種類/内容 *

補足が有ればご記入ください
貴社名*
ご担当者名 * 姓 名
メールアドレス *

ページTOPに戻る


目次

1 はじめに 39
1.1 調査の目的 39
1.2 市場の定義 39
1.3 本調査の範囲 39
1.3.1 市場セグメンテーションおよび対象地域 40
1.3.2 調査対象および除外項目 41
1.3.3 調査対象期間 42
1.3.4 調査対象通貨 42
1.4 ステークホルダー 42
1.5 変更点の概要 43

2 概要 44
2.1 市場のハイライトと主要な洞察 44
2.2 主要市場参加者:戦略的動向の分析 46
2.3 ヒトオルガノイド市場における破壊的トレンド 47
2.4 高成長セグメント 48
2.5 地域別概況:市場規模、成長率、および予測 49

3 プレミアム・インサイト 51
3.1 ヒトオルガノイド市場の概要 51
3.2 北米:製品タイプ別・国別のヒトオルガノイド市場 52
3.3 ヒトオルガノイド市場:地域別の成長機会 53
3.4 ヒトオルガノイドモデル市場シェア(エンドユーザー別、2026年対2031年)(%) 54
3.5 ヒトオルガノイドサービス市場シェア(エンドユーザー別、2026年対2031年)(%) 54

4 市場の概要 55
4.1 はじめに 55
4.2 市場の動向 55
4.2.1 成長要因 56
4.2.1.1 ヒトに関連性の高い薬物試験および非動物実験によるエビデンスに対する需要の高まり 56
4.2.1.2 標準化されたオルガノイドの供給および外部委託による試験能力の拡大 57
4.2.2 制約要因 57
4.2.2.1 モデル確立にかかる高コストと実験のリードタイムの長期化 57
4.2.3 機会 58
4.2.3.1 機能的精密腫瘍学に向けた患者由来オルガノイドスクリーニング 58
4.2.3.2 免疫および非腫瘍学分野へのオルガノイド応用拡大 58
4.2.4 課題 59
4.2.4.1 再現性と目的適合性の予測的検証 59
4.3 未充足ニーズと未開拓領域 59
4.4 相互に関連する市場とセクター横断的な機会 60
4.5 ティア1/2/3の主要プレイヤーによる戦略的動き 61

5 業界の動向 62
5.1 ポーターの5つの力分析 62
5.1.1 新規参入の脅威 63
5.1.2 代替品の脅威 63
5.1.3 買い手の交渉力 63
5.1.4 供給者の交渉力 64
5.1.5 競合の激しさ 64
5.2 マクロ経済の見通し 64
5.2.1 はじめに 64
5.2.2 GDPの動向と予測 65
5.2.3 世界のヒトオルガノイド市場の動向 65
5.3 バリューチェーン分析 66
5.4 エコシステム分析 69
5.4.1 主要なヒトオルガノイドモデルおよびサービスプロバイダー一覧 70
5.4.2 主要オルガノイドプロバイダーの生産拠点および能力開発の動向 71
5.5 価格分析 71
5.5.1 製品・サービス別平均販売価格 72
5.6 2026年~2027年の主要な会議・イベント 73
5.7 顧客の事業に影響を与えるトレンド・ディスラプション 73
5.8 投資および資金調達のシナリオ 74
5.9 2025年の米国関税が世界の人工オルガノイド市場に与える影響 75
5.9.1 はじめに 75
5.9.2 価格への影響分析 76
5.9.3 地域への影響 76
5.9.3.1 北米 76
5.9.3.2 欧州 77
5.9.3.3 アジア太平洋 77
5.9.4 最終用途産業への影響 78
5.9.4.1 製薬・バイオテクノロジー企業 78
5.9.4.2 学術・研究機関 78
5.9.4.3 CRO/CRDMOおよびその他の研究分野のエンドユーザー 79

6 技術の進歩、AIがもたらす影響、イノベーション、および将来の応用 80
6.1 主要な新興技術 80
6.1.1 AIを活用したデジタル自動化・高スループットオルガノイドプラットフォーム 80
6.2 関連技術 80
6.2.1 オルガン・オン・チップ/マイクロ生理学的システム 80
6.2.2 先進的なスフェロイドおよび3Dマイクロ組織モデル 81
6.3 補完的技術 81
6.3.1 空間トランスクリプトミクスおよび空間オミクス 81
6.3.2 CRISPR/Cas ゲノム編集 82
6.4 技術・製品ロードマップ 82
6.5 特許分析 82
6.5.1 ヒトオルガノイド特許における主要出願人/権利者(企業)、2015年~2025年 83
6.6 将来の応用 84
6.7 AI/生成AIが世界のヒトオルガノイド市場に与える影響 85
6.7.1 主なユースケースと市場の可能性 86
6.7.2 世界のヒトオルガノイド市場におけるAI導入の事例研究 86
6.7.3 相互に関連する隣接エコシステムと市場プレイヤーへの影響 86
6.7.4 世界のヒトオルガノイド市場におけるジェネレーティブAI導入に対する顧客の準備状況 87

7 規制環境と持続可能性への取り組み 88
7.1 地域ごとの規制とコンプライアンス 88
7.1.1 規制機関、政府機関、およびその他の組織 89
7.1.2 業界基準 92
7.2 持続可能性への影響および規制政策の取り組み 93
7.3 認証、表示、および環境基準 94

8 顧客の動向と購買行動 95
8.1 意思決定プロセス 95
8.2 購入者のステークホルダーと購入評価基準 96
8.2.1 購入プロセスにおける主要なステークホルダー 96
8.2.2 エンドユーザー別、ヒトオルガノイドモデルの主要な購入基準 97
8.3 導入の障壁と内部的な課題 99
8.4 エンドユーザーからの未充足ニーズ 99
8.5 市場の収益性 100

9 ヒトオルガノイド市場:提供内容別 101
9.1 はじめに 102
9.2 オルガノイドモデル 102
9.2.1 すぐに使えるオルガノイドモデル 105
9.2.1.1 市場成長を牽引する、即用型オルガノイドモデルへの需要の高まり 105
9.2.2 カスタマイズ可能なオルガノイドモデル 107
9.2.2.1 市場の成長を支えるカスタマイズ可能なオルガノイドモデルへの需要の高まり 107
9.3 サービス 109
9.3.1 モデル開発サービス 112
9.3.1.1 カスタマイズされたヒトオルガノイドモデルへの需要の高まりが、モデル開発サービスの成長を牽引 112
9.3.2 オルガノイドモデルを用いた試験サービス 114

10 ヒトオルガノイドモデル市場(モデルタイプ別) 117
10.1 はじめに 118
10.2 肝臓モデル 118
10.2.1 創薬および毒性試験における肝臓オルガノイドモデルの利用拡大が市場成長を牽引 118
10.3 腸および大腸モデル 120
10.3.1 疾患モデリングおよび創薬スクリーニングにおける腸および大腸オルガノイドモデルの利用拡大が市場成長を牽引 120
10.4 腎臓モデル 122
10.4.1 疾患モデリングおよび薬剤毒性試験における腎臓オルガノイドモデルの利用拡大が市場成長を牽引 122
10.5 膵臓モデル 124
10.5.1 疾患モデリングおよび創薬における膵臓オルガノイドモデルの利用拡大が市場成長を牽引 124
10.6 肺モデル 126
10.6.1 疾患モデリングおよび薬剤スクリーニングにおける肺オルガノイドモデルの利用拡大が市場成長を牽引 126
10.7 心臓モデル 128
10.7.1 市場成長を牽引する、心血管研究における心臓オルガノイドモデルの利用拡大 128
10.8 その他のオルガノイドモデル 130

11 ヒトオルガノイドモデル市場:培養タイプ別 133
11.1 はじめに 134
11.2 ECM/マトリゲルを用いた培養 134
11.2.1 ECM/マトリゲルを用いた培養法の普及がヒトオルガノイド市場の成長を牽引 134
11.3 気液界面培養 136
11.3.1 気液界面培養の採用拡大が市場成長を牽引 136
11.4 懸濁培養 138
11.4.1 市場成長を牽引する、スケーラブルなオルガノイド生産への需要の高まり 138
11.5 その他の培養法 140

12 ヒトオルガノイドモデル市場(由来別) 143
12.1 はじめに 144
12.2 多能性幹細胞 144
12.2.1 組織特異的オルガノイド作製における多能性幹細胞の利用拡大が市場成長を牽引 144
12.3 成体幹細胞 146
12.3.1 生理学的に関連性の高いオルガノイドモデルにおける成体幹細胞の利用拡大が市場成長を牽引 146
12.4 胚性幹細胞 148
12.4.1 発生および疾患研究における胚性幹細胞由来オルガノイドの利用拡大が市場成長を支える 148
12.5 その他の供給源 150

13 疾患分野別ヒトオルガノイド市場 153
13.1 はじめに 154
13.2 腫瘍学 154
13.2.1 疾患モデリングおよび創薬における腫瘍オルガノイドの採用拡大が市場成長を牽引 154
13.3 肝疾患/肝臓疾患 157
13.3.1 疾患モデリングおよび創薬における肝臓オルガノイドの採用拡大が市場成長を牽引 157
13.4 消化器疾患 159
13.4.1 炎症性腸疾患および悪性腫瘍のモデル化における広範な活用が市場を牽引 159
13.5 心血管疾患 161
13.5.1 心血管疾患の罹患率上昇が市場を牽引 161
13.6 感染症 163
13.6.1 抗ウイルス薬の開発におけるオルガノイドの活用が市場成長を後押し 163
13.7 神経疾患 165
13.7.1 神経精神疾患の罹患率の増加がヒトオルガノイドの採用を促進 165
13.8 その他の疾患領域 167

14 ヒトオルガノイド市場:用途別 170
14.1 はじめに 171
14.2 創薬とスクリーニング 171
14.2.1 創薬およびスクリーニングにおけるヒトオルガノイドの利用拡大が市場成長を牽引 171
14.3 薬剤の毒性および安全性試験 173
14.3.1 薬剤の毒性および安全性試験におけるヒトオルガノイドの利用拡大が市場成長を支える 173
14.4 疾患モデリング 175
14.4.1 疾患モデリングにおけるヒトオルガノイドの応用拡大が市場成長を牽引 175
14.5 発生生物学 177
14.5.1 市場成長を支える発生生物学におけるヒトオルガノイドの利用拡大 177
14.6 個別化医療 179
14.6.1 個別化医療における患者由来オルガノイドの採用拡大が市場成長を牽引 179
14.7 再生医療 181
14.7.1 再生医療および組織工学におけるヒトオルガノイドの応用拡大が市場成長を後押し 181
14.8 その他の応用 183

15 ヒトオルガノイドモデル市場(エンドユーザー別) 186
15.1 はじめに 187
15.2 製薬・バイオテクノロジー企業 187
15.2.1 製薬・バイオテクノロジー企業によるヒトオルガノイドモデルの採用拡大が市場成長を牽引 187
15.3 学術・研究機関 189
15.3.1 学術・研究機関におけるヒトオルガノイドの利用拡大が市場成長を牽引 189
15.4 CROS/CRDMOS 191
15.4.1 研究活動のアウトソーシング増加が、CROS/CRDMOSによるヒトオルガノイドモデルの採用を促進 191
15.5 その他のエンドユーザー 193

16 ヒトオルガノイドサービス市場:エンドユーザー別 196
16.1 はじめに 197
16.2 製薬・バイオテクノロジー企業 197
16.2.1 オルガノイドの開発および試験のアウトソーシング増加が市場成長を牽引 197
16.3 学術・研究機関 199
16.3.1 学術・研究機関におけるオルガノイドサービスの利用拡大が市場成長を牽引 199
16.4 CROS/CRDMOS 201
16.4.1 前臨床研究のアウトソーシング増加が、CROS/CRDMOSによるオルガノイドサービスの採用を促進 201
16.5 その他のエンドユーザー 203

17 ヒトオルガノイド市場:地域別 206
17.1 はじめに 207
17.2 北米 207
17.2.1 米国 213
17.2.1.1 医薬品開発におけるヒトオルガノイドの採用拡大が市場成長を牽引 213
17.2.2 カナダ 217
17.2.2.1 カナダにおける市場成長を支えるオルガノイド研究活動の拡大 217
17.3 ヨーロッパ 222
17.3.1 ドイツ 227
17.3.1.1 市場成長を支える強力な製薬・研究エコシステム 227
17.3.2 英国 231
17.3.2.1 市場成長を牽引するオルガノイド研究および創薬活動の拡大 231
17.3.3 フランス 236
17.3.3.1 市場成長を支えるライフサイエンス研究およびオルガノイド応用分野の拡大 236
17.3.4 イタリア 240
17.3.4.1 イタリアにおけるヒトオルガノイドの採用を促進する生物医学研究の拡大 240
17.3.5 スペイン 245
17.3.5.1 市場成長を支える生物医学研究におけるオルガノイドの利用拡大 245
17.3.6 その他の欧州諸国 249
17.3.6.1 市場成長を支える欧州各国におけるオルガノイド研究の拡大 249
17.4 アジア太平洋地域 254
17.4.1 中国 260
17.4.1.1 市場成長を牽引する製薬研究開発およびオルガノイド研究の拡大 260
17.4.2 日本 264
17.4.2.1 市場成長を支える再生医療および医薬品研究の進展 264
17.4.3 インド 269
17.4.3.1 市場成長を牽引する製薬研究およびバイオテクノロジー活動の拡大 269
17.4.4 韓国 273
17.4.4.1 ヒトオルガノイド市場の成長を支えるバイオテクノロジー投資の拡大 273
17.4.5 オーストラリア 278
17.4.5.1 オーストラリアにおける市場成長を支える生物医学研究の拡大 278
17.4.6 アジア太平洋その他の地域 282
17.4.6.1 市場成長を支えるバイオテクノロジー研究および医薬品開発活動の拡大 282
17.5 ラテンアメリカ 287
17.5.1 ブラジル 292
17.5.1.1 ヒトオルガノイド市場の成長を支える生物医学研究の拡大 292
17.5.2 メキシコ 296
17.5.2.1 メキシコにおける市場成長を牽引する医薬品研究の拡大 296
17.5.3 その他のラテンアメリカ 301
17.5.3.1 メキシコにおける市場成長を牽引する医薬品研究の拡大 301
17.6 中東・アフリカ 306
17.6.1 市場成長を支えるライフサイエンス研究への投資拡大 306

18 競争環境 311
18.1 はじめに 311
18.2 主要企業の戦略/競争優位性 311
18.2.1 ヒトオルガノイド市場における各企業の戦略の概要 311
18.3 売上高分析(2023年~2025年) 313
18.4 市場シェア分析(2025年) 314
18.5 企業評価マトリックス:主要プレイヤー(2025年) 315
18.5.1 スター企業 315
18.5.2 新興リーダー企業 315
18.5.3 広範な事業展開を行う企業 315
18.5.4 参入企業 315
18.5.5 主要企業の事業展開状況、2025年 317
18.5.5.1 企業の事業展開 317
18.5.5.2 地域別事業展開 317
18.5.5.3 提供サービス別事業展開 318
18.5.5.4 調達先別事業展開 319
18.5.5.5 アプリケーションの展開状況 320
18.6 企業評価マトリックス:スタートアップ/中小企業、2025年 321
18.6.1 先進的な企業 321
18.6.2 対応力のある企業 321
18.6.3 ダイナミックな企業 321
18.6.4 スタート地点にある企業 321
18.6.5 スタートアップ/中小企業プレイヤーの競合ベンチマーキング(2025年) 323
18.6.5.1 主要なスタートアップ/中小企業の詳細リスト 323
18.6.5.2 主要スタートアップ/中小企業の競合ベンチマーク 324
18.7 企業評価および財務指標 325
18.8 ブランド比較分析 326
18.9 競争シナリオ 327
18.9.1 製品・サービスの立ち上げ 327
18.9.2 取引 327
18.9.3 その他の動向 328

19 企業概要 329
19.1 主要企業 329
19.1.1 メルク(MERCK KGAA) 329
19.1.1.1 事業概要 329
19.1.1.2 提供製品・サービス 330
19.1.1.3 最近の動向 331
19.1.1.3.1 取引 331
19.1.1.3.2 事業拡大 332
19.1.1.4 MnMの見解 332
19.1.1.4.1 勝利への権利 332
19.1.1.4.2 戦略的選択 332
19.1.1.4.3 弱点と競合上の脅威 333
19.1.2 ダナハー・コーポレーション 334
19.1.2.1 事業概要 334
19.1.2.2 提供製品・サービス 335
19.1.2.3 最近の動向 336
19.1.2.3.1 その他の動向 336
19.1.2.4 MnMの見解 336
19.1.2.4.1 勝利への権利 336
19.1.2.4.2 戦略的選択 336
19.1.2.4.3 弱点と競合上の脅威 336
19.1.3 サムスン・バイオロジクス 337
19.1.3.1 事業概要 337
19.1.3.2 提供製品・サービス 338
19.1.3.3 最近の動向 339
19.1.3.3.1 サービスの開始 339
19.1.3.4 MnMの見解 339
19.1.3.4.1 勝利への権利 339
19.1.3.4.2 戦略的選択 339
19.1.3.4.3 弱点と競合上の脅威 340
19.1.4 WUXI APPTEC 341
19.1.4.1 事業概要 341
19.1.4.2 提供製品・サービス 342
19.1.4.3 最近の動向 343
19.1.4.3.1 その他の動向 343
19.1.4.4 MnMの見解 343
19.1.4.4.1 勝利への権利 343
19.1.4.4.2 戦略的選択 343
19.1.4.4.3 弱点と競合上の脅威 344
19.1.5 EVOTEC SE 345
19.1.5.1 事業概要 345
19.1.5.2 提供製品・サービス 346
19.1.5.3 最近の動向 347
19.1.5.3.1 取引 347
19.1.5.4 MnMの見解 347
19.1.5.4.1 勝利への権利 347
19.1.5.4.2 戦略的選択 347
19.1.5.4.3 弱点と競合上の脅威 347
19.1.6 CHAMPIONS ONCOLOGY 348
19.1.6.1 事業概要 348
19.1.6.2 提供製品・サービス 348
19.1.6.3 最近の動向 349
19.1.6.3.1 その他の動向 349
19.1.7 ACROBIOSYSTEMS 350
19.1.7.1 事業概要 350
19.1.7.2 提供製品・サービス 352
19.1.8 BIOMORGAN LIMITED 353
19.1.8.1 事業概要 353
19.1.8.2 提供製品・サービス 353
19.1.8.3 最近の動向 354
19.1.8.3.1 取引 354
19.1.9 オルガノイド・サイエンシズ社 355
19.1.9.1 事業概要 355
19.1.9.2 提供製品・サービス 356
19.1.9.3 最近の動向 357
19.1.9.3.1 事業拡大 357
19.1.9.3.2 その他の動向 357
19.1.10 JSR CORPORATION 358
19.1.10.1 事業概要 358
19.1.10.2 提供製品・サービス 358
19.1.10.3 最近の動向 359
19.1.10.3.1 取引 359
19.1.11 サーモフィッシャーサイエンティフィック社 360
19.1.11.1 事業概要 360
19.1.11.2 提供製品・サービス 361
19.1.11.3 最近の動向 362
19.1.11.3.1 新製品の発売 362
19.1.11.3.2 取引 362
19.1.12 ブルカー・コーポレーション 364
19.1.12.1 事業概要 364
19.1.12.2 提供製品・サービス 365
19.1.12.3 最近の動向 366
19.1.12.3.1 製品・サービスの発売 366
19.1.12.3.2 取引 366
19.1.13 チャールズ・リバー・ラボラトリーズ 367
19.1.13.1 事業概要 367
19.1.13.2 提供製品・サービス 368
19.1.14 ファーマロン 369
19.1.14.1 事業概要 369
19.1.14.2 提供製品・サービス 370
19.1.15 ヴィヴォシム・ラボラトリーズ社 371
19.1.15.1 事業概要 371
19.1.15.2 提供製品・サービス 371
19.1.15.3 最近の動向 372
19.1.15.3.1 製品発売 372
19.1.15.3.2 取引 372
19.1.16 STEMCELL TECHNOLOGIES 373
19.1.16.1 事業概要 373
19.1.16.2 提供製品・サービス 373
19.1.16.2.1 事業拡大 374
19.2 その他の主要企業 375
19.2.1 SCREENIN3D 375
19.2.2 DISCOVERY LIFE SCIENCES 376
19.2.3 LIDE BIOTECH 376
19.2.4 INNOSER 377
19.2.5 CENSO BIOTECHNOLOGIES LTD 377
19.2.6 CREATIVE BIOLABS 378
19.2.7 PANDORUM TECHNOLOGIES PVT. LTD. 378
19.2.8 インビトロキュー 379
19.2.9 ネイロブラストGX LLC 380
19.2.10 デクソルゲン 381
19.2.11 ピクスルバイオ 381

20 研究方法論 382
20.1 調査データ 382
20.2 調査手法 382
20.2.1 二次データ 382
20.2.1.1 主要な二次情報源 383
20.2.1.2 二次調査による主要データ 383
20.2.2 一次データ 383
20.2.2.1 一次情報源による主要データ 384
20.2.2.2 一次インタビューの内訳 384
20.3 市場規模の推計 385
20.3.1 2025年の世界のヒトオルガノイド市場規模の推計 385
20.3.1.1 手法1:企業売上高分析に基づく推計(ボトムアップ法) 385
20.3.1.2 手法2:二次調査 386
20.3.1.3 手法3:一次調査 386
20.3.1.4 主要な業界インサイト 387
20.3.1.5 手法3:MnMリポジトリ分析 387
20.3.2 セグメント別市場規模の推計(2025年) 388
20.4 市場成長率の予測 389
20.4.1 CAGR(年平均成長率)の予測 390
20.5 データの三角測量 391
20.6 調査の前提条件 392
20.7 調査の限界 393
20.8 リスク評価 394

21 付録 395
21.1 ディスカッション・ガイド 395
21.2 ナレッジストア:MarketsandMarketsのサブスクリプション・ポータル 401
21.3 カスタマイズオプション 403
21.4 関連レポート 403
21.5 著者詳細 404

ページTOPに戻る



図表リスト

FIGURE 1 HUMAN ORGANOIDS MARKET SEGMENTATION 40.
FIGURE 2 HUMAN ORGANOIDS MARKET: YEARS CONSIDERED 42.
FIGURE 3 MARKET SCENARIO 44.
FIGURE 4 GLOBAL HUMAN ORGANOID MODELS MARKET, 2023–2031 45.
FIGURE 5 GLOBAL HUMAN ORGANOID SERVICES MARKET, 2023–2031 45.
FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN ORGANOIDS MARKET, 2023–2026 46.
FIGURE 7 DISRUPTIONS INFLUENCING GROWTH OF HUMAN ORGANOIDS MARKET 47.
FIGURE 8 HIGH-GROWTH SEGMENTS IN HUMAN ORGANOIDS MARKET, 2026–2031 48.
FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN HUMAN ORGANOID MODELS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 49.
FIGURE 10 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN HUMAN ORGANOID SERVICES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 50.
FIGURE 11 INCREASING ADOPTION OF HUMAN ORGANOID MODELS IN DRUG DISCOVERY TO PROPEL THE HUMAN ORGANOIDS MARKET 51.
FIGURE 12 US AND SERVICES ACCOUNTED FOR LARGEST SHARE OF THE HUMAN ORGANOIDS MARKET IN NORTH AMERICA IN 2025 52.
FIGURE 13 ASIA PACIFIC LIKELY TO BE FASTEST-GROWING REGION DURING FORECAST PERIOD 53.
FIGURE 14 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD 54.
FIGURE 15 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD 54.
FIGURE 16 HUMAN ORGANOIDS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,.
AND CHALLENGES 55.
FIGURE 17 GLOBAL HUMAN ORGANOIDS MARKET: PORTER’S FIVE FORCES ANALYSIS 62.
FIGURE 18 GLOBAL HUMAN ORGANOID MODELS MARKET: VALUE CHAIN ANALYSIS 66.
FIGURE 19 GLOBAL HUMAN ORGANOIDS SERVICES MARKET: VALUE CHAIN ANALYSIS 68.
FIGURE 20 GLOBAL HUMAN ORGANOIDS MARKET: ECOSYSTEM ANALYSIS 70.
FIGURE 21 HUMAN ORGANOIDS MARKET: TRENDS/DISRUPTIONS IMPACTING.
CUSTOMER BUSINESS 74.
FIGURE 22 TOP APPLICANTS & OWNERS (COMPANIES) FOR HUMAN ORGANOIDS PATENTS, 2015–DECEMBER 2025 83.
FIGURE 23 IMPACT OF AI/GEN AI ON THE GLOBAL HUMAN ORGANOIDS MARKET 85.
FIGURE 24 ILLUSTRATIVE STAKEHOLDER INFLUENCE, BY OFFERING 96.
FIGURE 25 ILLUSTRATIVE BUYING PRIORITIES, BY END USER 97.
FIGURE 26 NORTH AMERICA: HUMAN ORGANOIDS MARKET SNAPSHOT 208.
FIGURE 27 ASIA PACIFIC: HUMAN ORGANOIDS MARKET SNAPSHOT 255.
FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN HUMAN ORGANOIDS MARKET.
(2023–2025) 313.
FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HUMAN ORGANOIDS MARKET (2025) 314.
FIGURE 30 HUMAN ORGANOIDS MARKET: COMPANY EVALUATION MATRIX.
(KEY PLAYERS), 2025 316.
FIGURE 31 HUMAN ORGANOIDS MARKET: COMPANY FOOTPRINT 317.
FIGURE 32 HUMAN ORGANOIDS MARKET: COMPANY EVALUATION MATRIX.
(STARTUPS/SMES), 2025 322.
FIGURE 33 EV/EBITDA OF KEY VENDORS 325.
FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 325.
FIGURE 35 HUMAN ORGANOIDS MARKET: BRAND COMPARISON 326.
FIGURE 36 MERCK: COMPANY SNAPSHOT 330.
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT 335.
FIGURE 38 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT 338.
FIGURE 39 WUXI APPTEC: COMPANY SNAPSHOT 342.
FIGURE 40 EVOTEC SE: COMPANY SNAPSHOT 346.
FIGURE 41 ACROBIOSYSTEMS: COMPANY SNAPSHOT 351.
FIGURE 42 ORGANOID SCIENCES, INC.: COMPANY SNAPSHOT 356.
FIGURE 43 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT 361.
FIGURE 44 BRUKER CORPORATION: COMPANY SNAPSHOT 365.
FIGURE 45 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT 368.
FIGURE 46 PHARMARON: COMPANY SNAPSHOT 370.
FIGURE 47 HUMAN ORGANOIDS MARKET: RESEARCH DESIGN METHODOLOGY 382.
FIGURE 48 HUMAN OGRANOIDS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 384.
FIGURE 49 GLOBAL HUMAN ORGANOIDS MARKET ESTIMATION, 2025 385.
FIGURE 50 HUMAN ORGANOIDS MARKET: COMPANY REVENUE ANALYSIS.
(BOTTOM-UP APPROACH) (2025) 386.
FIGURE 51 HUMAN ORGANOIDS MARKET: INSIGHTS FROM PRIMARIES 387.
FIGURE 52 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 388.
FIGURE 53 HUMAN ORGANOIDS MARKET: CAGR PROJECTIONS 390.
FIGURE 54 DATA TRIANGULATION METHODOLOGY 392.
TABLE 1 HUMAN ORGANOIDS MARKET: INCLUSIONS & EXCLUSIONS 41.
TABLE 2 HUMAN ORGANOIDS MARKET: IMPACT ANALYSIS 56.
TABLE 3 GLOBAL HUMAN ORGANOIDS MARKET: PORTER’S FIVE FORCES ANALYSIS 63.
TABLE 4 GLOBAL HUMAN ORGANOIDS MARKET: KEY MODEL AND SERVICE PROVIDERS 70.
TABLE 5 GLOBAL HUMAN ORGANOIDS MARKET: PRODUCTION SITES AND CAPABILITY DEVELOPMENTS 71.
TABLE 6 AVERAGE SELLING PRICE OF HUMAN ORGANOIDS, BY PRODUCT/ SERVICE, 2025 72.
TABLE 7 GLOBAL HUMAN ORGANOIDS MARKET: KEY CONFERENCES & EVENTS,.
2026–2027 73.
TABLE 8 HUMAN ORGANOIDS MARKET: INDICATIVE LIST OF PATENTS, 2024–2025 84.
TABLE 9 CASE STUDIES OF AI IMPLEMENTATION IN THE GLOBAL HUMAN ORGANOIDS MARKET 86.
TABLE 10 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN THE GLOBAL HUMAN ORGANOIDS MARKET 87.
TABLE 11 HUMAN ORGANOIDS REGULATORY GUIDANCE/FRAMEWORK, BY OFFERING 88.
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89.
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90.
TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91.
TABLE 15 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92.
TABLE 16 ILLUSTRATIVE STAKEHOLDER INFLUENCE, BY MODEL TYPE (%) 96.
TABLE 17 ILLUSTRATIVE BUYING CRITERIA, BY END USER 97.
TABLE 18 HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION) 102.
TABLE 19 HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION) 103.
TABLE 20 HUMAN ORGANOID MODELS MARKET, BY REGION, 2023–2031 (USD MILLION) 103.
TABLE 21 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 103.
TABLE 22 EUROPE: HUMAN ORGANOID MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 104.
TABLE 23 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 104.
TABLE 24 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 105.
TABLE 25 READY-TO-USE HUMAN ORGANOID MODELS MARKET, BY REGION,.
2023–2031 (USD MILLION) 105.
TABLE 26 NORTH AMERICA: READY-TO-USE HUMAN ORGANOID MODELS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 106.
TABLE 27 EUROPE: READY-TO-USE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 106.
TABLE 28 ASIA PACIFIC: READY-TO-USE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 107.
TABLE 29 LATIN AMERICA: READY-TO-USE HUMAN ORGANOID MODELS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 107.
TABLE 30 CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET, BY REGION,.
2023–2031 (USD MILLION) 108.
TABLE 31 NORTH AMERICA: CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 108.
TABLE 32 EUROPE: CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 108.
TABLE 33 ASIA PACIFIC: CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 109.
TABLE 34 LATIN AMERICA: CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 109.
TABLE 35 HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,.
2023–2031 (USD MILLION) 110.
TABLE 36 HUMAN ORGANOID MODEL SERVICES MARKET, BY REGION,.
2023–2031 (USD MILLION) 110.
TABLE 37 NORTH AMERICA: HUMAN ORGANOID MODEL SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 110.
TABLE 38 EUROPE: HUMAN ORGANOID MODEL SERVICES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 111.
TABLE 39 ASIA PACIFIC: HUMAN ORGANOID MODEL SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 111.
TABLE 40 LATIN AMERICA: HUMAN ORGANOID MODEL SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 112.
TABLE 41 HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 112.
TABLE 42 NORTH AMERICA: HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 113.
TABLE 43 EUROPE: HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 113.
TABLE 44 ASIA PACIFIC: HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 114.
TABLE 45 LATIN AMERICA: HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 114.
TABLE 46 HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 115.
TABLE 47 NORTH AMERICA: HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 115.
TABLE 48 EUROPE: HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 115.
TABLE 49 ASIA PACIFIC: HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 116.
TABLE 50 LATIN AMERICA: HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 116.
TABLE 51 HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,.
2023–2031 (USD MILLION) 118.
TABLE 52 LIVER MODELS MARKET, BY REGION, 2023–2031 (USD MILLION) 119.
TABLE 53 NORTH AMERICA: LIVER MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 119.
TABLE 54 EUROPE: LIVER MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 119.
TABLE 55 ASIA PACIFIC: LIVER MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 120.
TABLE 56 LATIN AMERICA: LIVER MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 120.
TABLE 57 INTESTINAL & COLORECTAL MODELS MARKET, BY REGION,.
2023–2031 (USD MILLION) 121.
TABLE 58 NORTH AMERICA: INTESTINAL & COLORECTAL MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 121.
TABLE 59 EUROPE: INTESTINAL & COLORECTAL MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 121.
TABLE 60 ASIA PACIFIC: INTESTINAL & COLORECTAL MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 122.
TABLE 61 LATIN AMERICA: INTESTINAL & COLORECTAL MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 122.
TABLE 62 KIDNEY MODELS MARKET, BY REGION, 2023–2031 (USD MILLION) 123.
TABLE 63 NORTH AMERICA: KIDNEY MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 123.
TABLE 64 EUROPE: KIDNEY MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 123.
TABLE 65 ASIA PACIFIC: KIDNEY MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 124.
TABLE 66 LATIN AMERICA: KIDNEY MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 124.
TABLE 67 PANCREATIC MODELS MARKET, BY REGION, 2023–2031 (USD MILLION) 125.
TABLE 68 NORTH AMERICA: PANCREATIC MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 125.
TABLE 69 EUROPE: PANCREATIC MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 125.
TABLE 70 ASIA PACIFIC: PANCREATIC MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 126.
TABLE 71 LATIN AMERICA: PANCREATIC MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 126.
TABLE 72 LUNG MODELS MARKET, BY REGION, 2023–2031 (USD MILLION) 127.
TABLE 73 NORTH AMERICA: LUNG MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 127.
TABLE 74 EUROPE: LUNG MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 127.
TABLE 75 ASIA PACIFIC: LUNG MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 128.
TABLE 76 LATIN AMERICA: LUNG MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 128.
TABLE 77 HEART MODELS MARKET, BY REGION, 2023–2031 (USD MILLION) 129.
TABLE 78 NORTH AMERICA: HEART MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 129.
TABLE 79 EUROPE: HEART MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 129.
TABLE 80 ASIA PACIFIC: HEART MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 130.
TABLE 81 LATIN AMERICA: HEART MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 130.
TABLE 82 OTHER HUMAN ORGANOID MODELS MARKET, BY REGION,.
2023–2031 (USD MILLION) 131.
TABLE 83 NORTH AMERICA: OTHER HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 131.
TABLE 84 EUROPE: OTHER HUMAN ORGANOID MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 131.
TABLE 85 ASIA PACIFIC: OTHER HUMAN ORGANOID MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 132.
TABLE 86 LATIN AMERICA: OTHER HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 132.
TABLE 87 HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,.
2023–2031 (USD MILLION) 134.
TABLE 88 HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE,.
BY REGION, 2023–2031 (USD MILLION) 135.
TABLE 89 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE, BY COUNTRY, 2023–2031 (USD MILLION) 135.
TABLE 90 EUROPE: HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE, BY COUNTRY, 2023–2031 (USD MILLION) 135.
TABLE 91 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE, BY COUNTRY, 2023–2031 (USD MILLION) 136.
TABLE 92 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE, BY COUNTRY, 2023–2031 (USD MILLION) 136.
TABLE 93 HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE, BY REGION, 2023–2031 (USD MILLION) 137.
TABLE 94 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE, BY COUNTRY, 2023–2031 (USD MILLION) 137.
TABLE 95 EUROPE: HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE,.
BY COUNTRY, 2023–2031 (USD MILLION) 137.
TABLE 96 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE, BY COUNTRY, 2023–2031 (USD MILLION) 138.
TABLE 97 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE, BY COUNTRY, 2023–2031 (USD MILLION) 138.
TABLE 98 HUMAN ORGANOID MODELS MARKET FOR SUSPENSION, BY REGION,.
2023–2031 (USD MILLION) 139.
TABLE 99 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR SUSPENSION,.
BY COUNTRY, 2023–2031 (USD MILLION) 139.
TABLE 100 EUROPE: HUMAN ORGANOID MODELS MARKET FOR SUSPENSION, BY COUNTRY, 2023–2031 (USD MILLION) 139.
TABLE 101 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR SUSPENSION,.
BY COUNTRY, 2023–2031 (USD MILLION) 140.
TABLE 102 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR SUSPENSION,.
BY COUNTRY, 2023–2031 (USD MILLION) 140.
TABLE 103 HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES, BY REGION, 2023–2031 (USD MILLION) 141.
TABLE 104 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES, BY COUNTRY, 2023–2031 (USD MILLION) 141.
TABLE 105 EUROPE: HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES,.
BY COUNTRY, 2023–2031 (USD MILLION) 141.
TABLE 106 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES, BY COUNTRY, 2023–2031 (USD MILLION) 142.
TABLE 107 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES, BY COUNTRY, 2023–2031 (USD MILLION) 142.
TABLE 108 HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION) 144.
TABLE 109 PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET,.
BY REGION, 2023–2031 (USD MILLION) 145.
TABLE 110 NORTH AMERICA: PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 145.
TABLE 111 EUROPE: PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 145.
TABLE 112 ASIA PACIFIC: PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 146.
TABLE 113 LATIN AMERICA: PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 146.
TABLE 114 ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY REGION, 2023–2031 (USD MILLION) 147.
TABLE 115 NORTH AMERICA: ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 147.
TABLE 116 EUROPE: ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 147.
TABLE 117 ASIA PACIFIC: ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 148.
TABLE 118 LATIN AMERICA: ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 148.
TABLE 119 EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET,.
BY REGION, 2023–2031 (USD MILLION) 149.
TABLE 120 NORTH AMERICA: EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 149.
TABLE 121 EUROPE: EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 149.
TABLE 122 ASIA PACIFIC: EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 150.
TABLE 123 LATIN AMERICA: EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 150.
TABLE 124 OTHER HUMAN ORGANOID MODEL SOURCES MARKET, BY REGION,.
2023–2031 (USD MILLION) 151.
TABLE 125 NORTH AMERICA: OTHER HUMAN ORGANOID MODEL SOURCES MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 151.
TABLE 126 EUROPE: OTHER HUMAN ORGANOID MODEL SOURCES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 151.
TABLE 127 ASIA PACIFIC: OTHER HUMAN ORGANOID MODEL SOURCES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 152.
TABLE 128 LATIN AMERICA: OTHER HUMAN ORGANOID MODEL SOURCES MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 152.
TABLE 129 HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION) 154.
TABLE 130 INCIDENCE OF CANCER CASES WORLDWIDE, IN 2022 VS 2045, BY CANCER TYPE 155.
TABLE 131 HUMAN ORGANOID MARKET FOR ONCOLOGY, BY REGION,.
2023–2031 (USD MILLION) 155.
TABLE 132 NORTH AMERICA: HUMAN ORGANOID MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 155.
TABLE 133 EUROPE: HUMAN ORGANOID MARKET FOR ONCOLOGY, BY COUNTRY,.
2023–2031 (USD MILLION) 156.
TABLE 134 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR ONCOLOGY, BY COUNTRY,.
2023–2031 (USD MILLION) 156.
TABLE 135 LATIN AMERICA: HUMAN ORGANOID MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 157.
TABLE 136 HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY REGION, 2023–2031 (USD MILLION) 157.
TABLE 137 NORTH AMERICA: HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY COUNTRY,.
2023–2031 (USD MILLION) 158.
TABLE 138 EUROPE: HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 158.
TABLE 139 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 159.
TABLE 140 LATIN AMERICA: HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY COUNTRY,.
2023–2031 (USD MILLION) 159.
TABLE 141 HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2031 (USD MILLION) 160.
TABLE 142 NORTH AMERICA: HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 160.
TABLE 143 EUROPE: HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 160.
TABLE 144 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 161.
TABLE 145 LATIN AMERICA: HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 161.
TABLE 146 HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2031 (USD MILLION) 162.
TABLE 147 NORTH AMERICA: HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 162.
TABLE 148 EUROPE: HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 162.
TABLE 149 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 163.
TABLE 150 LATIN AMERICA: HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 163.
TABLE 151 HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES, BY REGION,.
2023–2031 (USD MILLION) 164.
TABLE 152 NORTH AMERICA: HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 164.
TABLE 153 EUROPE: HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 164.
TABLE 154 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 165.
TABLE 155 LATIN AMERICA: HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 165.
TABLE 156 HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS, BY REGION,.
2023–2031 (USD MILLION) 166.
TABLE 157 NORTH AMERICA: HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 166.
TABLE 158 EUROPE: HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 166.
TABLE 159 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 167.
TABLE 160 LATIN AMERICA: HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 167.
TABLE 161 HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS, BY REGION,.
2023–2031 (USD MILLION) 168.
TABLE 162 NORTH AMERICA: HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS,.
BY COUNTRY, 2023–2031 (USD MILLION) 168.
TABLE 163 EUROPE: HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2023–2031 (USD MILLION) 168.
TABLE 164 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS,.
BY COUNTRY, 2023–2031 (USD MILLION) 169.
TABLE 165 LATIN AMERICA: HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS,.
BY COUNTRY, 2023–2031 (USD MILLION) 169.
TABLE 166 HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 171.
TABLE 167 HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING, BY REGION, 2023–2031 (USD MILLION) 172.
TABLE 168 NORTH AMERICA: HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING, BY COUNTRY, 2023–2031 (USD MILLION) 172.
TABLE 169 EUROPE: HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING,.
BY COUNTRY, 2023–2031 (USD MILLION) 172.
TABLE 170 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING, BY COUNTRY, 2023–2031 (USD MILLION) 173.
TABLE 171 LATIN AMERICA: HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING, BY COUNTRY, 2023–2031 (USD MILLION) 173.
TABLE 172 HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING, BY REGION, 2023–2031 (USD MILLION) 174.
TABLE 173 NORTH AMERICA: HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING, BY COUNTRY, 2023–2031 (USD MILLION) 174.
TABLE 174 EUROPE: HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING,.
BY COUNTRY, 2023–2031 (USD MILLION) 174.
TABLE 175 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING, BY COUNTRY, 2023–2031 (USD MILLION) 175.
TABLE 176 LATIN AMERICA: HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING, BY COUNTRY, 2023–2031 (USD MILLION) 175.
TABLE 177 HUMAN ORGANOID MARKET FOR DISEASE MODELING, BY REGION,.
2023–2031 (USD MILLION) 176.
TABLE 178 NORTH AMERICA: HUMAN ORGANOID MARKET FOR DISEASE MODELING,.
BY COUNTRY, 2023–2031 (USD MILLION) 176.
TABLE 179 EUROPE: HUMAN ORGANOID MARKET FOR DISEASE MODELING, BY COUNTRY, 2023–2031 (USD MILLION) 176.
TABLE 180 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR DISEASE MODELING, BY COUNTRY, 2023–2031 (USD MILLION) 177.
TABLE 181 LATIN AMERICA: HUMAN ORGANOID MARKET FOR DISEASE MODELING,.
BY COUNTRY, 2023–2031 (USD MILLION) 177.
TABLE 182 HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION,.
2023–2031 (USD MILLION) 178.
TABLE 183 NORTH AMERICA: HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 178.
TABLE 184 EUROPE: HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 178.
TABLE 185 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 179.
TABLE 186 LATIN AMERICA: HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 179.
TABLE 187 HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE, BY REGION,.
2023–2031 (USD MILLION) 180.
TABLE 188 NORTH AMERICA: HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE,.
BY COUNTRY, 2023–2031 (USD MILLION) 180.
TABLE 189 EUROPE: HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE,.
BY COUNTRY, 2023–2031 (USD MILLION) 180.
TABLE 190 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE,.
BY COUNTRY, 2023–2031 (USD MILLION) 181.
TABLE 191 LATIN AMERICA: HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE,.
BY COUNTRY, 2023–2031 (USD MILLION) 181.
TABLE 192 HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE, BY REGION,.
2023–2031 (USD MILLION) 182.
TABLE 193 NORTH AMERICA: HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE,.
BY COUNTRY, 2023–2031 (USD MILLION) 182.
TABLE 194 EUROPE: HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE,.
BY COUNTRY, 2023–2031 (USD MILLION) 182.
TABLE 195 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE,.
BY COUNTRY, 2023–2031 (USD MILLION) 183.
TABLE 196 LATIN AMERICA: HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE,.
BY COUNTRY, 2023–2031 (USD MILLION) 183.
TABLE 197 HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS, BY REGION,.
2023–2031 (USD MILLION) 184.
TABLE 198 NORTH AMERICA: HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS,.
BY COUNTRY, 2023–2031 (USD MILLION) 184.
TABLE 199 EUROPE: HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 184.
TABLE 200 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS,.
BY COUNTRY, 2023–2031 (USD MILLION) 185.
TABLE 201 LATIN AMERICA: HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS,.
BY COUNTRY, 2023–2031 (USD MILLION) 185.
TABLE 202 HUMAN ORGANOIDS MODELS MARKET, BY END USER,.
2023–2031 (USD MILLION) 187.
TABLE 203 HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2031 (USD MILLION) 188.
TABLE 204 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 188.
TABLE 205 EUROPE: HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 188.
TABLE 206 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 189.
TABLE 207 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 189.
TABLE 208 HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2031 (USD MILLION) 190.
TABLE 209 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 190.
TABLE 210 EUROPE: HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 190.
TABLE 211 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 191.
TABLE 212 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 191.
TABLE 213 HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS, BY REGION,.
2023–2031 (USD MILLION) 192.
TABLE 214 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS,.
BY COUNTRY, 2023–2031 (USD MILLION) 192.
TABLE 215 EUROPE: HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS,.
BY COUNTRY, 2023–2031 (USD MILLION) 192.
TABLE 216 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS,.
BY COUNTRY, 2023–2031 (USD MILLION) 193.
TABLE 217 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS,.
BY COUNTRY, 2023–2031 (USD MILLION) 193.
TABLE 218 HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS, BY REGION,.
2023–2031 (USD MILLION) 194.
TABLE 219 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 194.
TABLE 220 EUROPE: HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 194.
TABLE 221 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 195.
TABLE 222 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 195.
TABLE 223 HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 197.
TABLE 224 HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2031 (USD MILLION) 198.
TABLE 225 NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 198.
TABLE 226 EUROPE: HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 198.
TABLE 227 ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 199.
TABLE 228 LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 199.
TABLE 229 HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2031 (USD MILLION) 200.
TABLE 230 NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 200.
TABLE 231 EUROPE: HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 200.
TABLE 232 ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 201.
TABLE 233 LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 201.
TABLE 234 HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS, BY REGION,.
2023–2031 (USD MILLION) 202.
TABLE 235 NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS,.
BY COUNTRY, 2023–2031 (USD MILLION) 202.
TABLE 236 EUROPE: HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS,.
BY COUNTRY, 2023–2031 (USD MILLION) 202.
TABLE 237 ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS,.
BY COUNTRY, 2023–2031 (USD MILLION) 203.
TABLE 238 LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS,.
BY COUNTRY, 2023–2031 (USD MILLION) 203.
TABLE 239 HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2031 (USD MILLION) 204.
TABLE 240 NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 204.
TABLE 241 EUROPE: HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 204.
TABLE 242 ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 205.
TABLE 243 LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 205.
TABLE 244 HUMAN ORGANOIDS MARKET, BY REGION, 2023–2031 (USD MILLION) 207.
TABLE 245 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 208.
TABLE 246 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY OFFERING,.
2023–2031 (USD MILLION) 209.
TABLE 247 NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,.
2023–2031 (USD MILLION) 209.
TABLE 248 NORTH AMERICA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION) 209.
TABLE 249 NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,.
2023–2031 (USD MILLION) 210.
TABLE 250 NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION) 210.
TABLE 251 NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,.
2023–2031 (USD MILLION) 211.
TABLE 252 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,.
2023–2031 (USD MILLION) 211.
TABLE 253 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 212.
TABLE 254 NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY END USER,.
2023–2031 (USD MILLION) 212.
TABLE 255 NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 213.
TABLE 256 US: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION) 213.
TABLE 257 US: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION) 214.
TABLE 258 US: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,.
2023–2031 (USD MILLION) 214.
TABLE 259 US: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,.
2023–2031 (USD MILLION) 214.
TABLE 260 US: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,.
2023–2031 (USD MILLION) 215.
TABLE 261 US: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,.
2023–2031 (USD MILLION) 215.
TABLE 262 US: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION) 216.
TABLE 263 US: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 216.
TABLE 264 US: HUMAN ORGANOIDS MODELS MARKET, BY END USER,.
2023–2031 (USD MILLION) 217.
TABLE 265 US: HUMAN ORGANOID SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 217.
TABLE 266 CANADA: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION) 218.
TABLE 267 CANADA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,.
2023–2031 (USD MILLION) 218.
TABLE 268 CANADA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,.
2023–2031 (USD MILLION) 218.
TABLE 269 CANADA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,.
2023–2031 (USD MILLION) 219.
TABLE 270 CANADA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,.
2023–2031 (USD MILLION) 219.
TABLE 271 CANADA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,.
2023–2031 (USD MILLION) 220.
TABLE 272 CANADA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,.
2023–2031 (USD MILLION) 220.
TABLE 273 CANADA: HUMAN ORGANOIDS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 221.
TABLE 274 CANADA: HUMAN ORGANOIDS MODELS MARKET, BY END USER,.
2023–2031 (USD MILLION) 221.
TABLE 275 CANADA: HUMAN ORGANOID SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 222.
TABLE 276 EUROPE: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 222.
TABLE 277 EUROPE: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION) 223.
TABLE 278 EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,.
2023–2031 (USD MILLION) 223.
TABLE 279 EUROPE: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,.
2023–2031 (USD MILLION) 223.

 

ページTOPに戻る


 

Summary

The global human organoids market is projected to reach USD 0.90 billion by 2031 from USD 0.29 billion in 2026, at a CAGR of 25.6%. The global human organoids market is expected to expand during the forecast period as pharmaceutical and research organizations adopt models that capture key features of human tissue biology. The study covers finished organoid models and model development and organoid-based testing services for medical and pharmaceutical applications. Separately sold media, reagents, consumables, and instruments are excluded, as are cosmetic, veterinary, food, agricultural, and environmental uses. The FDA’s April 2025 roadmap supports evaluating validated non-animal methods, including organoid toxicity testing. Demand for disease-specific models and scalable screening creates opportunities for suppliers. Costs, specialized expertise, batch variability, and incomplete tissue maturation can limit adoption and require careful validation.

Ready-to-use and customizable organoid models support access to human-relevant research systems.
Based on offerings, the market is segmented into organoid models and services. The models segment covers ready-to-use and customizable organoids supplied as finished products. Services include model development and organoid model-based testing. Researchers purchasing models can conduct experiments in their own laboratories, while outsourced services provide specialized development and screening capabilities. Molecular Devices (US), a Danaher company, supplies assay-ready organoids and custom expansion services. HUB Organoids (Netherlands), part of Merck KGaA (Germany), provides custom model development and drug screening. Model quality, donor characteristics, and assay suitability influence purchasing decisions across pharmaceutical companies, research institutes, and CROs/CRDMOs.

Intestinal and colorectal organoid models address gastrointestinal research and oncology screening needs.
Based on model type, the study covers liver, intestinal & colorectal, kidney, pancreatic, lung, heart, and other organoid models. Other models include brain, retinal, breast, and skin organoids. Intestinal and colorectal models enable researchers to investigate epithelial function, disease mechanisms, and drug response in patient-relevant systems. Molecular Devices (US) offers assay-ready colorectal cancer and intestinal organoid lines, illustrating commercial access to finished models. Kidney organoids also support renal disease research, as demonstrated by Evotec’s (Germany) iPSC-derived kidney organoid capabilities. Demand across model types depends on tissue function, disease coverage, and suitability for the intended experimental endpoints.

Organoid research services are expanding opportunities in Asia Pacific during the forecast period.
The regional scope comprises North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Asia Pacific offers opportunities as providers expand human organoid-based drug discovery services. Samsung Biologics (South Korea) launched Samsung Organoids in June 2025, extending its services into preclinical research through patient-derived tumor organoid screening. WuXi AppTec (China), through WuXi Biology, develops xenograft-derived organoid models for in vitro oncology screening. These capabilities support demand for disease-relevant models and outsourced therapeutic evaluation. Growth across the region will depend on research investment, access to patient material, model reproducibility, and validation of organoid methods for specific applications.

Primary research respondent categories for the human organoids study include:
- By Respondent: Supply-side providers of organoid models and services; demand-side users in pharmaceutical, biotechnology, and biomedical research organizations
- By Company Type: Diversified life science companies, CROs/CRDMOs, specialist organoid developers, and startups/SMEs
- By Designation: CXOs and directors, research and business managers, scientists, and other technical specialists
- By Region: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

List of Companies Covered in the Study
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Merck KGaA
- Eurofins Scientific
- WuXi AppTec
- Charles River Laboratories
- Bruker Corporation
- Pharmaron
- Evotec
- ACROBiosystems
- Samsung Biologics
- Other Players

Research Coverage
This report categorizes the human organoids market by offering, model type, culture type, source, disease area, application, end user, and region. Model and service end users are assessed separately. The study covers historical years 2023–2024, base year 2025, and forecasts for 2026–2031. It examines drivers, restraints, opportunities, challenges, pricing, funding, technological advances, AI applications, and regulatory developments. Competitive coverage includes company profiles, revenue and market share analysis, company evaluation matrices, offering footprints, and strategic developments. Market revenue is restricted to finished human organoid models and model development and testing services. General culture supplies and instruments are excluded from the market estimates.

Key Benefits of Buying the Report
The report helps established suppliers and new entrants assess revenue opportunities across finished organoid models and research services. It supports decisions on model portfolios, therapeutic focus, customer groups, and geographic expansion. Analysis of supplier capabilities, buying criteria, and adoption barriers helps stakeholders develop market entry and partnership strategies. The study also examines how standardization, scalable production, and validated testing methods may affect demand and competitive positioning.

The report provides insights into the following pointers:
- Analysis of key drivers (demand for human-relevant drug screening, patient-derived disease models, and validated alternatives to animal testing), restraints (model development costs and specialized expertise), opportunities (scalable organoid supply, personalized medicine research, and AI-assisted model standardization), and challenges (batch variability, limited tissue maturation, and cross-laboratory reproducibility) affecting the human organoids market.
- Product Development/Innovation: Insights into finished organoid models, model development and testing services, automation, and AI-assisted organoid workflows.
- Market Development: Assessment of opportunities for human organoid models and services across six regions and the countries included in the study scope.
- Market Diversification: Analysis of emerging disease models, research applications, underserved customer needs, funding, and geographic expansion opportunities.
- Competitive Assessment: Assessment of market positioning, growth strategies, and organoid offerings of companies, including Merck KGaA (Germany), Danaher Corporation (US), Samsung Biologics (South Korea), WuXi AppTec (China), and Evotec (Germany).



ページTOPに戻る


Table of Contents

1 INTRODUCTION 39
1.1 STUDY OBJECTIVES 39
1.2 MARKET DEFINITION 39
1.3 STUDY SCOPE 39
1.3.1 MARKETS SEGMENTATION & REGIONS COVERED 40
1.3.2 INCLUSIONS & EXCLUSIONS 41
1.3.3 YEARS CONSIDERED 42
1.3.4 CURRENCY CONSIDERED 42
1.4 STAKEHOLDERS 42
1.5 SUMMARY OF CHANGES 43

2 EXECUTIVE SUMMARY 44
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 44
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 46
2.3 DISRUPTIVE TRENDS IN HUMAN ORGANOIDS MARKET 47
2.4 HIGH-GROWTH SEGMENTS 48
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 49

3 PREMIUM INSIGHTS 51
3.1 HUMAN ORGANOIDS MARKET OVERVIEW 51
3.2 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY PRODUCT TYPE AND COUNTRY 52
3.3 HUMAN ORGANOIDS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
3.4 HUMAN ORGANOIDS MODELS MARKET SHARE, BY END USER, 2026 VS 2031 (%) 54
3.5 HUMAN ORGANOIDS SERVICES MARKET SHARE, BY END USER, 2026 VS 2031 (%) 54

4 MARKET OVERVIEW 55
4.1 INTRODUCTION 55
4.2 MARKET DYNAMICS 55
4.2.1 DRIVERS 56
4.2.1.1 Growing demand for human-relevant drug testing and non-animal evidence 56
4.2.1.2 Expansion of standardized organoid supply and outsourced testing capacity 57
4.2.2 RESTRAINTS 57
4.2.2.1 High model establishment costs and lengthy experimental turnaround 57
4.2.3 OPPORTUNITIES 58
4.2.3.1 Patient-linked organoid screening for functional precision oncology 58
4.2.3.2 Expansion into immune and non-oncology organoid applications 58
4.2.4 CHALLENGES 59
4.2.4.1 Reproducibility and fit-for-purpose predictive validation 59
4.3 UNMET NEEDS AND WHITE SPACES 59
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 60
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 61

5 INDUSTRY TRENDS 62
5.1 PORTER’S FIVE FORCES ANALYSIS 62
5.1.1 THREAT OF NEW ENTRANTS 63
5.1.2 THREAT OF SUBSTITUTES 63
5.1.3 BARGAINING POWER OF BUYERS 63
5.1.4 BARGAINING POWER OF SUPPLIERS 64
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 64
5.2 MACROECONOMIC OUTLOOK 64
5.2.1 INTRODUCTION 64
5.2.2 GDP TRENDS AND FORECAST 65
5.2.3 TRENDS IN THE GLOBAL HUMAN ORGANOIDS MARKET 65
5.3 VALUE CHAIN ANALYSIS 66
5.4 ECOSYSTEM ANALYSIS 69
5.4.1 LIST OF KEY HUMAN ORGANOID MODEL AND SERVICE PROVIDERS 70
5.4.2 PRODUCTION SITES AND CAPABILITY DEVELOPMENTS OF KEY ORGANOID PROVIDERS 71
5.5 PRICING ANALYSIS 71
5.5.1 AVERAGE SELLING PRICE, BY PRODUC/ SERVICE 72
5.6 KEY CONFERENCES & EVENTS, 2026–2027 73
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 73
5.8 INVESTMENT & FUNDING SCENARIO 74
5.9 IMPACT OF 2025 US TARIFFS—GLOBAL HUMAN ORGANOIDS MARKET 75
5.9.1 INTRODUCTION 75
5.9.2 PRICE IMPACT ANALYSIS 76
5.9.3 IMPACT ON REGIONS 76
5.9.3.1 North America 76
5.9.3.2 Europe 77
5.9.3.3 Asia Pacific 77
5.9.4 IMPACT ON END-USE INDUSTRIES 78
5.9.4.1 Pharmaceutical and Biotechnology Companies 78
5.9.4.2 Academic and Research Institutes 78
5.9.4.3 CROs/CRDMOs and Other Research End Users 79

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS, AND FUTURE APPLICATIONS 80
6.1 KEY EMERGING TECHNOLOGIES 80
6.1.1 AI-ENABLED AND DIGITAL AUTOMATED AND HIGH-THROUGHPUT ORGANOID PLATFORMS 80
6.2 ADJACENT TECHNOLOGIES 80
6.2.1 ORGAN-ON-CHIP/MICROPHYSIOLOGICAL SYSTEMS 80
6.2.2 ADVANCED SPHEROID & 3D MICROTISSUE MODELS 81
6.3 COMPLEMENTARY TECHNOLOGIES 81
6.3.1 SPATIAL TRANSCRIPTOMICS AND SPATIAL OMICS 81
6.3.2 CRISPR/CAS GENOME EDITING 82
6.4 TECHNOLOGY/PRODUCT ROADMAP 82
6.5 PATENT ANALYSIS 82
6.5.1 TOP APPLICANTS/OWNERS (COMPANIES), FOR HUMAN ORGANOIDS PATENTS, 2015–2025 83
6.6 FUTURE APPLICATIONS 84
6.7 IMPACT OF AI/GEN AI ON THE GLOBAL HUMAN ORGANOIDS MARKET 85
6.7.1 TOP USE CASES AND MARKET POTENTIAL 86
6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN THE GLOBAL HUMAN ORGANOIDS MARKET 86
6.7.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 86
6.7.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN THE GLOBAL HUMAN ORGANOIDS MARKET 87

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 88
7.1 REGIONAL REGULATIONS AND COMPLIANCE 88
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89
7.1.2 INDUSTRY STANDARDS 92
7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 93
7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 94

8 CUSTOMER LANDSCAPE & BUYING BEHAVIOR 95
8.1 DECISION-MAKING PROCESS 95
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 96
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 96
8.2.2 KEY BUYING CRITERIA FOR HUMAN ORGANOID MODELS, BY END USER 97
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 99
8.4 UNMET NEEDS FROM END USERS 99
8.5 MARKET PROFITABILITY 100

9 HUMAN ORGANOIDS MARKET, BY OFFERING 101
9.1 INTRODUCTION 102
9.2 ORGANOID MODELS 102
9.2.1 READY-TO-USE ORGANOID MODELS 105
9.2.1.1 Increasing demand for ready-to-use organoid models to drive market growth 105
9.2.2 CUSTOMIZABLE ORGANOID MODELS 107
9.2.2.1 Rising demand for customizable organoid models to support market growth 107
9.3 SERVICES 109
9.3.1 MODEL DEVELOPMENT SERVICES 112
9.3.1.1 Rising demand for customized human organoid models to drive growth of model development services 112
9.3.2 ORGANOID MODEL-BASED TESTING SERVICES 114

10 HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE 117
10.1 INTRODUCTION 118
10.2 LIVER MODELS 118
10.2.1 RISING USE OF LIVER ORGANOID MODELS IN DRUG DISCOVERY AND TOXICITY TESTING TO DRIVE MARKET GROWTH 118
10.3 INTESTINAL & COLORECTAL MODELS 120
10.3.1 RISING USE OF INTESTINAL & COLORECTAL ORGANOID MODELS IN DISEASE MODELING AND DRUG SCREENING TO DRIVE MARKET GROWTH 120
10.4 KIDNEY MODELS 122
10.4.1 RISING USE OF KIDNEY ORGANOID MODELS IN DISEASE MODELING AND DRUG TOXICITY TESTING TO DRIVE MARKET GROWTH 122
10.5 PANCREATIC MODELS 124
10.5.1 RISING USE OF PANCREATIC ORGANOID MODELS IN DISEASE MODELING AND DRUG DISCOVERY TO DRIVE MARKET GROWTH 124
10.6 LUNG MODELS 126
10.6.1 RISING USE OF LUNG ORGANOID MODELS IN DISEASE MODELING AND DRUG SCREENING TO DRIVE MARKET GROWTH 126
10.7 HEART MODELS 128
10.7.1 RISING USE OF HEART ORGANOID MODELS IN CARDIOVASCULAR RESEARCH TO DRIVE MARKET GROWTH 128
10.8 OTHER ORGANOID MODELS 130

11 HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE 133
11.1 INTRODUCTION 134
11.2 ECM/MATRIGEL-BASED CULTURE 134
11.2.1 WIDESPREAD USE OF ECM/MATRIGEL-BASED CULTURE TO DRIVE HUMAN ORGANOIDS MARKET GROWTH 134
11.3 AIR-LIQUID INTERFACE CULTURE 136
11.3.1 INCREASING ADOPTION OF AIR-LIQUID INTERFACE CULTURE TO DRIVE MARKET GROWTH 136
11.4 SUSPENSION 138
11.4.1 RISING DEMAND FOR SCALABLE ORGANOID PRODUCTION TO DRIVE MARKET GROWTH 138
11.5 OTHER CULTURE TYPES 140

12 HUMAN ORGANOIDS MODELS MARKET, BY SOURCE 143
12.1 INTRODUCTION 144
12.2 PLURIPOTENT STEM CELLS 144
12.2.1 EXPANDING USE OF PLURIPOTENT STEM CELLS IN TISSUE-SPECIFIC ORGANOID DEVELOPMENT TO DRIVE MARKET GROWTH 144
12.3 ADULT STEM CELLS 146
12.3.1 RISING USE OF ADULT STEM CELLS FOR PHYSIOLOGICALLY RELEVANT ORGANOID MODELS TO DRIVE MARKET GROWTH 146
12.4 EMBRYONIC STEM CELLS 148
12.4.1 INCREASING USE OF EMBRYONIC STEM CELL-DERIVED ORGANOIDS IN DEVELOPMENTAL AND DISEASE RESEARCH TO SUPPORT MARKET GROWTH 148
12.5 OTHER SOURCES 150

13 HUMAN ORGANOIDS MARKET, BY DISEASE AREA 153
13.1 INTRODUCTION 154
13.2 ONCOLOGY 154
13.2.1 INCREASING ADOPTION OF TUMOR ORGANOIDS FOR DISEASE MODELING AND DRUG DEVELOPMENT TO DRIVE MARKET GROWTH 154
13.3 LIVER DISEASES/HEPATOLOGICAL DISORDERS 157
13.3.1 INCREASING ADOPTION OF LIVER ORGANOIDS FOR DISEASE MODELING AND DRUG DEVELOPMENT TO DRIVE MARKET GROWTH 157
13.4 GASTROINTESTINAL DISEASES 159
13.4.1 WIDE USAGE IN MODELING INFLAMMATORY BOWEL DISEASE AND MALIGNANCIES TO PROPEL MARKET 159
13.5 CARDIOVASCULAR DISEASES 161
13.5.1 RISING INCIDENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET 161
13.6 INFECTIOUS DISEASES 163
13.6.1 USE OF ORGANOIDS IN DEVELOPING ANTIVIRAL DRUGS TO SUPPORT MARKET GROWTH 163
13.7 NEUROLOGICAL DISORDERS 165
13.7.1 GROWING INCIDENCE OF NEUROPSYCHIATRIC DISORDERS TO FUEL UPTAKE OF HUMAN ORGANOIDS 165
13.8 OTHER DISEASE AREAS 167

14 HUMAN ORGANOIDS MARKET, BY APPLICATION 170
14.1 INTRODUCTION 171
14.2 DRUG DISCOVERY & SCREENING 171
14.2.1 RISING USE OF HUMAN ORGANOIDS IN DRUG DISCOVERY AND SCREENING TO DRIVE MARKET GROWTH 171
14.3 DRUG TOXICITY & SAFETY TESTING 173
14.3.1 RISING USE OF HUMAN ORGANOIDS FOR DRUG TOXICITY AND SAFETY TESTING TO SUPPORT MARKET GROWTH 173
14.4 DISEASE MODELING 175
14.4.1 RISING APPLICATION OF HUMAN ORGANOIDS IN DISEASE MODELING TO DRIVE MARKET GROWTH 175
14.5 DEVELOPMENTAL BIOLOGY 177
14.5.1 INCREASING USE OF HUMAN ORGANOIDS IN DEVELOPMENTAL BIOLOGY TO SUPPORT MARKET GROWTH 177
14.6 PERSONALIZED MEDICINE 179
14.6.1 RISING ADOPTION OF PATIENT-DERIVED ORGANOIDS FOR PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH 179
14.7 REGENERATIVE MEDICINE 181
14.7.1 EXPANDING APPLICATIONS OF HUMAN ORGANOIDS IN REGENERATIVE MEDICINE AND TISSUE ENGINEERING TO SUPPORT MARKET GROWTH 181
14.8 OTHER APPLICATIONS 183

15 HUMAN ORGANOID MODELS MARKET, BY END USER 186
15.1 INTRODUCTION 187
15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 187
15.2.1 INCREASING ADOPTION OF HUMAN ORGANOID MODELS BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DRIVE MARKET GROWTH 187
15.3 ACADEMIC & RESEARCH INSTITUTES 189
15.3.1 RISING USE OF HUMAN ORGANOIDS IN ACADEMIC AND RESEARCH INSTITUTES TO DRIVE MARKET GROWTH 189
15.4 CROS/CRDMOS 191
15.4.1 INCREASING OUTSOURCING OF RESEARCH ACTIVITIES TO DRIVE ADOPTION OF HUMAN ORGANOID MODELS BY CROS/CRDMOS 191
15.5 OTHER END USERS 193

16 HUMAN ORGANOID SERVICES MARKET, BY END USER 196
16.1 INTRODUCTION 197
16.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 197
16.2.1 INCREASING OUTSOURCING OF ORGANOID DEVELOPMENT AND TESTING TO DRIVE MARKET GROWTH 197
16.3 ACADEMIC & RESEARCH INSTITUTES 199
16.3.1 RISING USE OF ORGANOID SERVICES IN ACADEMIC AND RESEARCH INSTITUTES TO DRIVE MARKET GROWTH 199
16.4 CROS/CRDMOS 201
16.4.1 INCREASING OUTSOURCING OF PRECLINICAL RESEARCH TO DRIVE ADOPTION OF ORGANOID SERVICES BY CROS/CRDMOS 201
16.5 OTHER END USERS 203

17 HUMAN ORGANOIDS MARKET, BY REGION 206
17.1 INTRODUCTION 207
17.2 NORTH AMERICA 207
17.2.1 US 213
17.2.1.1 Increasing adoption of human organoids in drug development to drive market growth 213
17.2.2 CANADA 217
17.2.2.1 Growing organoid research activities to support market growth in Canada 217
17.3 EUROPE 222
17.3.1 GERMANY 227
17.3.1.1 Strong pharmaceutical and research ecosystem to support market growth 227
17.3.2 UK 231
17.3.2.1 Increasing organoid research and drug discovery activities to drive market growth 231
17.3.3 FRANCE 236
17.3.3.1 Growing life sciences research and organoid applications to support market growth 236
17.3.4 ITALY 240
17.3.4.1 Expanding biomedical research to drive adoption of human organoids in Italy 240
17.3.5 SPAIN 245
17.3.5.1 Rising use of organoids in biomedical research to support market growth 245
17.3.6 REST OF EUROPE 249
17.3.6.1 Expanding organoid research across european countries to support market growth 249
17.4 ASIA PACIFIC 254
17.4.1 CHINA 260
17.4.1.1 Increasing pharmaceutical R&D and organoid research to drive market growth 260
17.4.2 JAPAN 264
17.4.2.1 Advancing regenerative medicine and drug research to support market growth 264
17.4.3 INDIA 269
17.4.3.1 Expanding pharmaceutical research and biotechnology activities to drive market growth 269
17.4.4 SOUTH KOREA 273
17.4.4.1 Growing biotechnology investments to support human organoid market growth 273
17.4.5 AUSTRALIA 278
17.4.5.1 Increasing biomedical research to support market growth in Australia 278
17.4.6 REST OF ASIA PACIFIC 282
17.4.6.1 Rising biotechnology research and drug development activities to support market growth 282
17.5 LATIN AMERICA 287
17.5.1 BRAZIL 292
17.5.1.1 Growing biomedical research to support human organoid market growth 292
17.5.2 MEXICO 296
17.5.2.1 Expanding pharmaceutical research to drive market growth in Mexico 296
17.5.3 REST OF LATIN AMERICA 301
17.5.3.1 Expanding pharmaceutical research to drive market growth in Mexico 301
17.6 MIDDLE EAST & AFRICA 306
17.6.1 GROWING INVESTMENTS IN LIFE SCIENCES RESEARCH TO SUPPORT MARKET GROWTH 306

18 COMPETITIVE LANDSCAPE 311
18.1 INTRODUCTION 311
18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 311
18.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HUMAN ORGANOIDS MARKET 311
18.3 REVENUE ANALYSIS, 2023–2025 313
18.4 MARKET SHARE ANALYSIS, 2025 314
18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 315
18.5.1 STARS 315
18.5.2 EMERGING LEADERS 315
18.5.3 PERVASIVE PLAYERS 315
18.5.4 PARTICIPANTS 315
18.5.5 COMPANY FOOTPRINT, KEY PLAYERS, 2025 317
18.5.5.1 Company footprint 317
18.5.5.2 Region footprint 317
18.5.5.3 Offering footprint 318
18.5.5.4 Source footprint 319
18.5.5.5 Application footprint 320
18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 321
18.6.1 PROGRESSIVE COMPANIES 321
18.6.2 RESPONSIVE COMPANIES 321
18.6.3 DYNAMIC COMPANIES 321
18.6.4 STARTING BLOCKS 321
18.6.5 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, 2025 323
18.6.5.1 Detailed list of key startups/SMEs 323
18.6.5.2 Competitive benchmarking of key startups/SMEs 324
18.7 COMPANY VALUATION AND FINANCIAL METRICS 325
18.8 BRAND COMPARATIVE ANALYSIS 326
18.9 COMPETITIVE SCENARIO 327
18.9.1 PRODUCT/ SERVICE LAUNCHES 327
18.9.2 DEALS 327
18.9.3 OTHER DEVELOPMENTS 328

19 COMPANY PROFILES 329
19.1 KEY PLAYERS 329
19.1.1 MERCK KGAA 329
19.1.1.1 Business overview 329
19.1.1.2 Products/Services offered 330
19.1.1.3 Recent developments 331
19.1.1.3.1 Deals 331
19.1.1.3.2 Expansions 332
19.1.1.4 MnM view 332
19.1.1.4.1 Right to win 332
19.1.1.4.2 Strategic choices 332
19.1.1.4.3 Weaknesses and competitive threats 333
19.1.2 DANAHER CORPORATION 334
19.1.2.1 Business overview 334
19.1.2.2 Products/Services offered 335
19.1.2.3 Recent developments 336
19.1.2.3.1 Other developments 336
19.1.2.4 MnM view 336
19.1.2.4.1 Right to win 336
19.1.2.4.2 Strategic choices 336
19.1.2.4.3 Weaknesses and competitive threats 336
19.1.3 SAMSUNG BIOLOGICS 337
19.1.3.1 Business overview 337
19.1.3.2 Products/Services offered 338
19.1.3.3 Recent developments 339
19.1.3.3.1 Service launches 339
19.1.3.4 MnM view 339
19.1.3.4.1 Right to win 339
19.1.3.4.2 Strategic choices 339
19.1.3.4.3 Weaknesses and competitive threats 340
19.1.4 WUXI APPTEC 341
19.1.4.1 Business overview 341
19.1.4.2 Products/Services offered 342
19.1.4.3 Recent developments 343
19.1.4.3.1 Other developments 343
19.1.4.4 MnM view 343
19.1.4.4.1 Right to win 343
19.1.4.4.2 Strategic choices 343
19.1.4.4.3 Weaknesses and competitive threats 344
19.1.5 EVOTEC SE 345
19.1.5.1 Business overview 345
19.1.5.2 Products/Services offered 346
19.1.5.3 Recent developments 347
19.1.5.3.1 Deals 347
19.1.5.4 MnM view 347
19.1.5.4.1 Right to win 347
19.1.5.4.2 Strategic choices 347
19.1.5.4.3 Weaknesses and competitive threats 347
19.1.6 CHAMPIONS ONCOLOGY 348
19.1.6.1 Business overview 348
19.1.6.2 Products/Services offered 348
19.1.6.3 Recent developments 349
19.1.6.3.1 Other developments 349
19.1.7 ACROBIOSYSTEMS 350
19.1.7.1 Business overview 350
19.1.7.2 Products/Services offered 352
19.1.8 BIOMORGAN LIMITED 353
19.1.8.1 Business overview 353
19.1.8.2 Products/Services offered 353
19.1.8.3 Recent developments 354
19.1.8.3.1 Deals 354
19.1.9 ORGANOID SCIENCES, INC. 355
19.1.9.1 Business overview 355
19.1.9.2 Products/Services offered 356
19.1.9.3 Recent developments 357
19.1.9.3.1 Expansions 357
19.1.9.3.2 Other developments 357
19.1.10 JSR CORPORATION 358
19.1.10.1 Business overview 358
19.1.10.2 Products/Services offered 358
19.1.10.3 Recent developments 359
19.1.10.3.1 Deals 359
19.1.11 THERMO FISHER SCIENTIFIC INC. 360
19.1.11.1 Business overview 360
19.1.11.2 Products/Services offered 361
19.1.11.3 Recent developments 362
19.1.11.3.1 Product launches 362
19.1.11.3.2 Deals 362
19.1.12 BRUKER CORPORATION 364
19.1.12.1 Business overview 364
19.1.12.2 Products/Services offered 365
19.1.12.3 Recent developments 366
19.1.12.3.1 Product & service launches 366
19.1.12.3.2 Deals 366
19.1.13 CHARLES RIVER LABORATORIES 367
19.1.13.1 Business overview 367
19.1.13.2 Products/Services offered 368
19.1.14 PHARMARON 369
19.1.14.1 Business overview 369
19.1.14.2 Products/Services offered 370
19.1.15 VIVOSIM LABS, INC. 371
19.1.15.1 Business overview 371
19.1.15.2 Products/Services offered 371
19.1.15.3 Recent developments 372
19.1.15.3.1 Product launches 372
19.1.15.3.2 Deals 372
19.1.16 STEMCELL TECHNOLOGIES 373
19.1.16.1 Business overview 373
19.1.16.2 Products/Services offered 373
19.1.16.2.1 Expansions 374
19.2 OTHER PLAYERS 375
19.2.1 SCREENIN3D 375
19.2.2 DISCOVERY LIFE SCIENCES 376
19.2.3 LIDE BIOTECH 376
19.2.4 INNOSER 377
19.2.5 CENSO BIOTECHNOLOGIES LTD 377
19.2.6 CREATIVE BIOLABS 378
19.2.7 PANDORUM TECHNOLOGIES PVT. LTD. 378
19.2.8 INVITROCUE 379
19.2.9 NEYROBLASTGX LLC 380
19.2.10 DEXORGEN 381
19.2.11 PIXLBIO 381

20 RESEARCH METHODOLOGY 382
20.1 RESEARCH DATA 382
20.2 RESEARCH APPROACH 382
20.2.1 SECONDARY DATA 382
20.2.1.1 Key secondary sources 383
20.2.1.2 Key data from secondary research 383
20.2.2 PRIMARY DATA 383
20.2.2.1 Key data from primary sources 384
20.2.2.2 Breakdown of primary interviews 384
20.3 MARKET SIZE ESTIMATION 385
20.3.1 GLOBAL HUMAN ORGANOIDS MARKET ESTIMATION, 2025 385
20.3.1.1 Approach 1: company revenue analysis-based estimation (bottom-up) 385
20.3.1.2 Approach 2: secondary research 386
20.3.1.3 Approach 3: primary research 386
20.3.1.4 Key industry insights 387
20.3.1.5 Approach 3: MnM repository analysis 387
20.3.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025 388
20.4 MARKET GROWTH RATE PROJECTIONS 389
20.4.1 CAGR PROJECTIONS 390
20.5 DATA TRIANGULATION 391
20.6 RESEARCH ASSUMPTIONS 392
20.7 RESEARCH LIMITATIONS 393
20.8 RISK ASSESSMENT 394

21 APPENDIX 395
21.1 DISCUSSION GUIDE 395
21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 401
21.3 CUSTOMIZATION OPTIONS 403
21.4 RELATED REPORTS 403
21.5 AUTHOR DETAILS 404

ページTOPに戻る



List of Tables/Graphs

FIGURE 1 HUMAN ORGANOIDS MARKET SEGMENTATION 40.
FIGURE 2 HUMAN ORGANOIDS MARKET: YEARS CONSIDERED 42.
FIGURE 3 MARKET SCENARIO 44.
FIGURE 4 GLOBAL HUMAN ORGANOID MODELS MARKET, 2023–2031 45.
FIGURE 5 GLOBAL HUMAN ORGANOID SERVICES MARKET, 2023–2031 45.
FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN ORGANOIDS MARKET, 2023–2026 46.
FIGURE 7 DISRUPTIONS INFLUENCING GROWTH OF HUMAN ORGANOIDS MARKET 47.
FIGURE 8 HIGH-GROWTH SEGMENTS IN HUMAN ORGANOIDS MARKET, 2026–2031 48.
FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN HUMAN ORGANOID MODELS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 49.
FIGURE 10 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN HUMAN ORGANOID SERVICES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 50.
FIGURE 11 INCREASING ADOPTION OF HUMAN ORGANOID MODELS IN DRUG DISCOVERY TO PROPEL THE HUMAN ORGANOIDS MARKET 51.
FIGURE 12 US AND SERVICES ACCOUNTED FOR LARGEST SHARE OF THE HUMAN ORGANOIDS MARKET IN NORTH AMERICA IN 2025 52.
FIGURE 13 ASIA PACIFIC LIKELY TO BE FASTEST-GROWING REGION DURING FORECAST PERIOD 53.
FIGURE 14 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD 54.
FIGURE 15 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD 54.
FIGURE 16 HUMAN ORGANOIDS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,.
AND CHALLENGES 55.
FIGURE 17 GLOBAL HUMAN ORGANOIDS MARKET: PORTER’S FIVE FORCES ANALYSIS 62.
FIGURE 18 GLOBAL HUMAN ORGANOID MODELS MARKET: VALUE CHAIN ANALYSIS 66.
FIGURE 19 GLOBAL HUMAN ORGANOIDS SERVICES MARKET: VALUE CHAIN ANALYSIS 68.
FIGURE 20 GLOBAL HUMAN ORGANOIDS MARKET: ECOSYSTEM ANALYSIS 70.
FIGURE 21 HUMAN ORGANOIDS MARKET: TRENDS/DISRUPTIONS IMPACTING.
CUSTOMER BUSINESS 74.
FIGURE 22 TOP APPLICANTS & OWNERS (COMPANIES) FOR HUMAN ORGANOIDS PATENTS, 2015–DECEMBER 2025 83.
FIGURE 23 IMPACT OF AI/GEN AI ON THE GLOBAL HUMAN ORGANOIDS MARKET 85.
FIGURE 24 ILLUSTRATIVE STAKEHOLDER INFLUENCE, BY OFFERING 96.
FIGURE 25 ILLUSTRATIVE BUYING PRIORITIES, BY END USER 97.
FIGURE 26 NORTH AMERICA: HUMAN ORGANOIDS MARKET SNAPSHOT 208.
FIGURE 27 ASIA PACIFIC: HUMAN ORGANOIDS MARKET SNAPSHOT 255.
FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN HUMAN ORGANOIDS MARKET.
(2023–2025) 313.
FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HUMAN ORGANOIDS MARKET (2025) 314.
FIGURE 30 HUMAN ORGANOIDS MARKET: COMPANY EVALUATION MATRIX.
(KEY PLAYERS), 2025 316.
FIGURE 31 HUMAN ORGANOIDS MARKET: COMPANY FOOTPRINT 317.
FIGURE 32 HUMAN ORGANOIDS MARKET: COMPANY EVALUATION MATRIX.
(STARTUPS/SMES), 2025 322.
FIGURE 33 EV/EBITDA OF KEY VENDORS 325.
FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 325.
FIGURE 35 HUMAN ORGANOIDS MARKET: BRAND COMPARISON 326.
FIGURE 36 MERCK: COMPANY SNAPSHOT 330.
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT 335.
FIGURE 38 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT 338.
FIGURE 39 WUXI APPTEC: COMPANY SNAPSHOT 342.
FIGURE 40 EVOTEC SE: COMPANY SNAPSHOT 346.
FIGURE 41 ACROBIOSYSTEMS: COMPANY SNAPSHOT 351.
FIGURE 42 ORGANOID SCIENCES, INC.: COMPANY SNAPSHOT 356.
FIGURE 43 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT 361.
FIGURE 44 BRUKER CORPORATION: COMPANY SNAPSHOT 365.
FIGURE 45 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT 368.
FIGURE 46 PHARMARON: COMPANY SNAPSHOT 370.
FIGURE 47 HUMAN ORGANOIDS MARKET: RESEARCH DESIGN METHODOLOGY 382.
FIGURE 48 HUMAN OGRANOIDS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 384.
FIGURE 49 GLOBAL HUMAN ORGANOIDS MARKET ESTIMATION, 2025 385.
FIGURE 50 HUMAN ORGANOIDS MARKET: COMPANY REVENUE ANALYSIS.
(BOTTOM-UP APPROACH) (2025) 386.
FIGURE 51 HUMAN ORGANOIDS MARKET: INSIGHTS FROM PRIMARIES 387.
FIGURE 52 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 388.
FIGURE 53 HUMAN ORGANOIDS MARKET: CAGR PROJECTIONS 390.
FIGURE 54 DATA TRIANGULATION METHODOLOGY 392.
TABLE 1 HUMAN ORGANOIDS MARKET: INCLUSIONS & EXCLUSIONS 41.
TABLE 2 HUMAN ORGANOIDS MARKET: IMPACT ANALYSIS 56.
TABLE 3 GLOBAL HUMAN ORGANOIDS MARKET: PORTER’S FIVE FORCES ANALYSIS 63.
TABLE 4 GLOBAL HUMAN ORGANOIDS MARKET: KEY MODEL AND SERVICE PROVIDERS 70.
TABLE 5 GLOBAL HUMAN ORGANOIDS MARKET: PRODUCTION SITES AND CAPABILITY DEVELOPMENTS 71.
TABLE 6 AVERAGE SELLING PRICE OF HUMAN ORGANOIDS, BY PRODUCT/ SERVICE, 2025 72.
TABLE 7 GLOBAL HUMAN ORGANOIDS MARKET: KEY CONFERENCES & EVENTS,.
2026–2027 73.
TABLE 8 HUMAN ORGANOIDS MARKET: INDICATIVE LIST OF PATENTS, 2024–2025 84.
TABLE 9 CASE STUDIES OF AI IMPLEMENTATION IN THE GLOBAL HUMAN ORGANOIDS MARKET 86.
TABLE 10 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN THE GLOBAL HUMAN ORGANOIDS MARKET 87.
TABLE 11 HUMAN ORGANOIDS REGULATORY GUIDANCE/FRAMEWORK, BY OFFERING 88.
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89.
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90.
TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91.
TABLE 15 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92.
TABLE 16 ILLUSTRATIVE STAKEHOLDER INFLUENCE, BY MODEL TYPE (%) 96.
TABLE 17 ILLUSTRATIVE BUYING CRITERIA, BY END USER 97.
TABLE 18 HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION) 102.
TABLE 19 HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION) 103.
TABLE 20 HUMAN ORGANOID MODELS MARKET, BY REGION, 2023–2031 (USD MILLION) 103.
TABLE 21 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 103.
TABLE 22 EUROPE: HUMAN ORGANOID MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 104.
TABLE 23 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 104.
TABLE 24 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 105.
TABLE 25 READY-TO-USE HUMAN ORGANOID MODELS MARKET, BY REGION,.
2023–2031 (USD MILLION) 105.
TABLE 26 NORTH AMERICA: READY-TO-USE HUMAN ORGANOID MODELS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 106.
TABLE 27 EUROPE: READY-TO-USE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 106.
TABLE 28 ASIA PACIFIC: READY-TO-USE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 107.
TABLE 29 LATIN AMERICA: READY-TO-USE HUMAN ORGANOID MODELS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 107.
TABLE 30 CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET, BY REGION,.
2023–2031 (USD MILLION) 108.
TABLE 31 NORTH AMERICA: CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 108.
TABLE 32 EUROPE: CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 108.
TABLE 33 ASIA PACIFIC: CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 109.
TABLE 34 LATIN AMERICA: CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 109.
TABLE 35 HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,.
2023–2031 (USD MILLION) 110.
TABLE 36 HUMAN ORGANOID MODEL SERVICES MARKET, BY REGION,.
2023–2031 (USD MILLION) 110.
TABLE 37 NORTH AMERICA: HUMAN ORGANOID MODEL SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 110.
TABLE 38 EUROPE: HUMAN ORGANOID MODEL SERVICES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 111.
TABLE 39 ASIA PACIFIC: HUMAN ORGANOID MODEL SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 111.
TABLE 40 LATIN AMERICA: HUMAN ORGANOID MODEL SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 112.
TABLE 41 HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 112.
TABLE 42 NORTH AMERICA: HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 113.
TABLE 43 EUROPE: HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 113.
TABLE 44 ASIA PACIFIC: HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 114.
TABLE 45 LATIN AMERICA: HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 114.
TABLE 46 HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 115.
TABLE 47 NORTH AMERICA: HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 115.
TABLE 48 EUROPE: HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 115.
TABLE 49 ASIA PACIFIC: HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 116.
TABLE 50 LATIN AMERICA: HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 116.
TABLE 51 HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,.
2023–2031 (USD MILLION) 118.
TABLE 52 LIVER MODELS MARKET, BY REGION, 2023–2031 (USD MILLION) 119.
TABLE 53 NORTH AMERICA: LIVER MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 119.
TABLE 54 EUROPE: LIVER MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 119.
TABLE 55 ASIA PACIFIC: LIVER MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 120.
TABLE 56 LATIN AMERICA: LIVER MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 120.
TABLE 57 INTESTINAL & COLORECTAL MODELS MARKET, BY REGION,.
2023–2031 (USD MILLION) 121.
TABLE 58 NORTH AMERICA: INTESTINAL & COLORECTAL MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 121.
TABLE 59 EUROPE: INTESTINAL & COLORECTAL MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 121.
TABLE 60 ASIA PACIFIC: INTESTINAL & COLORECTAL MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 122.
TABLE 61 LATIN AMERICA: INTESTINAL & COLORECTAL MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 122.
TABLE 62 KIDNEY MODELS MARKET, BY REGION, 2023–2031 (USD MILLION) 123.
TABLE 63 NORTH AMERICA: KIDNEY MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 123.
TABLE 64 EUROPE: KIDNEY MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 123.
TABLE 65 ASIA PACIFIC: KIDNEY MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 124.
TABLE 66 LATIN AMERICA: KIDNEY MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 124.
TABLE 67 PANCREATIC MODELS MARKET, BY REGION, 2023–2031 (USD MILLION) 125.
TABLE 68 NORTH AMERICA: PANCREATIC MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 125.
TABLE 69 EUROPE: PANCREATIC MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 125.
TABLE 70 ASIA PACIFIC: PANCREATIC MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 126.
TABLE 71 LATIN AMERICA: PANCREATIC MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 126.
TABLE 72 LUNG MODELS MARKET, BY REGION, 2023–2031 (USD MILLION) 127.
TABLE 73 NORTH AMERICA: LUNG MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 127.
TABLE 74 EUROPE: LUNG MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 127.
TABLE 75 ASIA PACIFIC: LUNG MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 128.
TABLE 76 LATIN AMERICA: LUNG MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 128.
TABLE 77 HEART MODELS MARKET, BY REGION, 2023–2031 (USD MILLION) 129.
TABLE 78 NORTH AMERICA: HEART MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 129.
TABLE 79 EUROPE: HEART MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 129.
TABLE 80 ASIA PACIFIC: HEART MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 130.
TABLE 81 LATIN AMERICA: HEART MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 130.
TABLE 82 OTHER HUMAN ORGANOID MODELS MARKET, BY REGION,.
2023–2031 (USD MILLION) 131.
TABLE 83 NORTH AMERICA: OTHER HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 131.
TABLE 84 EUROPE: OTHER HUMAN ORGANOID MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 131.
TABLE 85 ASIA PACIFIC: OTHER HUMAN ORGANOID MODELS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 132.
TABLE 86 LATIN AMERICA: OTHER HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 132.
TABLE 87 HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,.
2023–2031 (USD MILLION) 134.
TABLE 88 HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE,.
BY REGION, 2023–2031 (USD MILLION) 135.
TABLE 89 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE, BY COUNTRY, 2023–2031 (USD MILLION) 135.
TABLE 90 EUROPE: HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE, BY COUNTRY, 2023–2031 (USD MILLION) 135.
TABLE 91 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE, BY COUNTRY, 2023–2031 (USD MILLION) 136.
TABLE 92 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE, BY COUNTRY, 2023–2031 (USD MILLION) 136.
TABLE 93 HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE, BY REGION, 2023–2031 (USD MILLION) 137.
TABLE 94 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE, BY COUNTRY, 2023–2031 (USD MILLION) 137.
TABLE 95 EUROPE: HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE,.
BY COUNTRY, 2023–2031 (USD MILLION) 137.
TABLE 96 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE, BY COUNTRY, 2023–2031 (USD MILLION) 138.
TABLE 97 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE, BY COUNTRY, 2023–2031 (USD MILLION) 138.
TABLE 98 HUMAN ORGANOID MODELS MARKET FOR SUSPENSION, BY REGION,.
2023–2031 (USD MILLION) 139.
TABLE 99 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR SUSPENSION,.
BY COUNTRY, 2023–2031 (USD MILLION) 139.
TABLE 100 EUROPE: HUMAN ORGANOID MODELS MARKET FOR SUSPENSION, BY COUNTRY, 2023–2031 (USD MILLION) 139.
TABLE 101 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR SUSPENSION,.
BY COUNTRY, 2023–2031 (USD MILLION) 140.
TABLE 102 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR SUSPENSION,.
BY COUNTRY, 2023–2031 (USD MILLION) 140.
TABLE 103 HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES, BY REGION, 2023–2031 (USD MILLION) 141.
TABLE 104 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES, BY COUNTRY, 2023–2031 (USD MILLION) 141.
TABLE 105 EUROPE: HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES,.
BY COUNTRY, 2023–2031 (USD MILLION) 141.
TABLE 106 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES, BY COUNTRY, 2023–2031 (USD MILLION) 142.
TABLE 107 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES, BY COUNTRY, 2023–2031 (USD MILLION) 142.
TABLE 108 HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION) 144.
TABLE 109 PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET,.
BY REGION, 2023–2031 (USD MILLION) 145.
TABLE 110 NORTH AMERICA: PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 145.
TABLE 111 EUROPE: PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 145.
TABLE 112 ASIA PACIFIC: PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 146.
TABLE 113 LATIN AMERICA: PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 146.
TABLE 114 ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY REGION, 2023–2031 (USD MILLION) 147.
TABLE 115 NORTH AMERICA: ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 147.
TABLE 116 EUROPE: ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 147.
TABLE 117 ASIA PACIFIC: ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 148.
TABLE 118 LATIN AMERICA: ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 148.
TABLE 119 EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET,.
BY REGION, 2023–2031 (USD MILLION) 149.
TABLE 120 NORTH AMERICA: EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 149.
TABLE 121 EUROPE: EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 149.
TABLE 122 ASIA PACIFIC: EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 150.
TABLE 123 LATIN AMERICA: EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 150.
TABLE 124 OTHER HUMAN ORGANOID MODEL SOURCES MARKET, BY REGION,.
2023–2031 (USD MILLION) 151.
TABLE 125 NORTH AMERICA: OTHER HUMAN ORGANOID MODEL SOURCES MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 151.
TABLE 126 EUROPE: OTHER HUMAN ORGANOID MODEL SOURCES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 151.
TABLE 127 ASIA PACIFIC: OTHER HUMAN ORGANOID MODEL SOURCES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 152.
TABLE 128 LATIN AMERICA: OTHER HUMAN ORGANOID MODEL SOURCES MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 152.
TABLE 129 HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION) 154.
TABLE 130 INCIDENCE OF CANCER CASES WORLDWIDE, IN 2022 VS 2045, BY CANCER TYPE 155.
TABLE 131 HUMAN ORGANOID MARKET FOR ONCOLOGY, BY REGION,.
2023–2031 (USD MILLION) 155.
TABLE 132 NORTH AMERICA: HUMAN ORGANOID MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 155.
TABLE 133 EUROPE: HUMAN ORGANOID MARKET FOR ONCOLOGY, BY COUNTRY,.
2023–2031 (USD MILLION) 156.
TABLE 134 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR ONCOLOGY, BY COUNTRY,.
2023–2031 (USD MILLION) 156.
TABLE 135 LATIN AMERICA: HUMAN ORGANOID MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 157.
TABLE 136 HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY REGION, 2023–2031 (USD MILLION) 157.
TABLE 137 NORTH AMERICA: HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY COUNTRY,.
2023–2031 (USD MILLION) 158.
TABLE 138 EUROPE: HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 158.
TABLE 139 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 159.
TABLE 140 LATIN AMERICA: HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY COUNTRY,.
2023–2031 (USD MILLION) 159.
TABLE 141 HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2031 (USD MILLION) 160.
TABLE 142 NORTH AMERICA: HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 160.
TABLE 143 EUROPE: HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 160.
TABLE 144 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 161.
TABLE 145 LATIN AMERICA: HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 161.
TABLE 146 HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2031 (USD MILLION) 162.
TABLE 147 NORTH AMERICA: HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 162.
TABLE 148 EUROPE: HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 162.
TABLE 149 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 163.
TABLE 150 LATIN AMERICA: HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 163.
TABLE 151 HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES, BY REGION,.
2023–2031 (USD MILLION) 164.
TABLE 152 NORTH AMERICA: HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 164.
TABLE 153 EUROPE: HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 164.
TABLE 154 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 165.
TABLE 155 LATIN AMERICA: HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 165.
TABLE 156 HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS, BY REGION,.
2023–2031 (USD MILLION) 166.
TABLE 157 NORTH AMERICA: HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 166.
TABLE 158 EUROPE: HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 166.
TABLE 159 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 167.
TABLE 160 LATIN AMERICA: HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 167.
TABLE 161 HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS, BY REGION,.
2023–2031 (USD MILLION) 168.
TABLE 162 NORTH AMERICA: HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS,.
BY COUNTRY, 2023–2031 (USD MILLION) 168.
TABLE 163 EUROPE: HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2023–2031 (USD MILLION) 168.
TABLE 164 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS,.
BY COUNTRY, 2023–2031 (USD MILLION) 169.
TABLE 165 LATIN AMERICA: HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS,.
BY COUNTRY, 2023–2031 (USD MILLION) 169.
TABLE 166 HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 171.
TABLE 167 HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING, BY REGION, 2023–2031 (USD MILLION) 172.
TABLE 168 NORTH AMERICA: HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING, BY COUNTRY, 2023–2031 (USD MILLION) 172.
TABLE 169 EUROPE: HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING,.
BY COUNTRY, 2023–2031 (USD MILLION) 172.
TABLE 170 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING, BY COUNTRY, 2023–2031 (USD MILLION) 173.
TABLE 171 LATIN AMERICA: HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING, BY COUNTRY, 2023–2031 (USD MILLION) 173.
TABLE 172 HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING, BY REGION, 2023–2031 (USD MILLION) 174.
TABLE 173 NORTH AMERICA: HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING, BY COUNTRY, 2023–2031 (USD MILLION) 174.
TABLE 174 EUROPE: HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING,.
BY COUNTRY, 2023–2031 (USD MILLION) 174.
TABLE 175 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING, BY COUNTRY, 2023–2031 (USD MILLION) 175.
TABLE 176 LATIN AMERICA: HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING, BY COUNTRY, 2023–2031 (USD MILLION) 175.
TABLE 177 HUMAN ORGANOID MARKET FOR DISEASE MODELING, BY REGION,.
2023–2031 (USD MILLION) 176.
TABLE 178 NORTH AMERICA: HUMAN ORGANOID MARKET FOR DISEASE MODELING,.
BY COUNTRY, 2023–2031 (USD MILLION) 176.
TABLE 179 EUROPE: HUMAN ORGANOID MARKET FOR DISEASE MODELING, BY COUNTRY, 2023–2031 (USD MILLION) 176.
TABLE 180 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR DISEASE MODELING, BY COUNTRY, 2023–2031 (USD MILLION) 177.
TABLE 181 LATIN AMERICA: HUMAN ORGANOID MARKET FOR DISEASE MODELING,.
BY COUNTRY, 2023–2031 (USD MILLION) 177.
TABLE 182 HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION,.
2023–2031 (USD MILLION) 178.
TABLE 183 NORTH AMERICA: HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 178.
TABLE 184 EUROPE: HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 178.
TABLE 185 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 179.
TABLE 186 LATIN AMERICA: HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 179.
TABLE 187 HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE, BY REGION,.
2023–2031 (USD MILLION) 180.
TABLE 188 NORTH AMERICA: HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE,.
BY COUNTRY, 2023–2031 (USD MILLION) 180.
TABLE 189 EUROPE: HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE,.
BY COUNTRY, 2023–2031 (USD MILLION) 180.
TABLE 190 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE,.
BY COUNTRY, 2023–2031 (USD MILLION) 181.
TABLE 191 LATIN AMERICA: HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE,.
BY COUNTRY, 2023–2031 (USD MILLION) 181.
TABLE 192 HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE, BY REGION,.
2023–2031 (USD MILLION) 182.
TABLE 193 NORTH AMERICA: HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE,.
BY COUNTRY, 2023–2031 (USD MILLION) 182.
TABLE 194 EUROPE: HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE,.
BY COUNTRY, 2023–2031 (USD MILLION) 182.
TABLE 195 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE,.
BY COUNTRY, 2023–2031 (USD MILLION) 183.
TABLE 196 LATIN AMERICA: HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE,.
BY COUNTRY, 2023–2031 (USD MILLION) 183.
TABLE 197 HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS, BY REGION,.
2023–2031 (USD MILLION) 184.
TABLE 198 NORTH AMERICA: HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS,.
BY COUNTRY, 2023–2031 (USD MILLION) 184.
TABLE 199 EUROPE: HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 184.
TABLE 200 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS,.
BY COUNTRY, 2023–2031 (USD MILLION) 185.
TABLE 201 LATIN AMERICA: HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS,.
BY COUNTRY, 2023–2031 (USD MILLION) 185.
TABLE 202 HUMAN ORGANOIDS MODELS MARKET, BY END USER,.
2023–2031 (USD MILLION) 187.
TABLE 203 HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2031 (USD MILLION) 188.
TABLE 204 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 188.
TABLE 205 EUROPE: HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 188.
TABLE 206 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 189.
TABLE 207 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 189.
TABLE 208 HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2031 (USD MILLION) 190.
TABLE 209 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 190.
TABLE 210 EUROPE: HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 190.
TABLE 211 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 191.
TABLE 212 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 191.
TABLE 213 HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS, BY REGION,.
2023–2031 (USD MILLION) 192.
TABLE 214 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS,.
BY COUNTRY, 2023–2031 (USD MILLION) 192.
TABLE 215 EUROPE: HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS,.
BY COUNTRY, 2023–2031 (USD MILLION) 192.
TABLE 216 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS,.
BY COUNTRY, 2023–2031 (USD MILLION) 193.
TABLE 217 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS,.
BY COUNTRY, 2023–2031 (USD MILLION) 193.
TABLE 218 HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS, BY REGION,.
2023–2031 (USD MILLION) 194.
TABLE 219 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 194.
TABLE 220 EUROPE: HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 194.
TABLE 221 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 195.
TABLE 222 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 195.
TABLE 223 HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 197.
TABLE 224 HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2031 (USD MILLION) 198.
TABLE 225 NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 198.
TABLE 226 EUROPE: HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 198.
TABLE 227 ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 199.
TABLE 228 LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 199.
TABLE 229 HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2031 (USD MILLION) 200.
TABLE 230 NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 200.
TABLE 231 EUROPE: HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 200.
TABLE 232 ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 201.
TABLE 233 LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 201.
TABLE 234 HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS, BY REGION,.
2023–2031 (USD MILLION) 202.
TABLE 235 NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS,.
BY COUNTRY, 2023–2031 (USD MILLION) 202.
TABLE 236 EUROPE: HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS,.
BY COUNTRY, 2023–2031 (USD MILLION) 202.
TABLE 237 ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS,.
BY COUNTRY, 2023–2031 (USD MILLION) 203.
TABLE 238 LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS,.
BY COUNTRY, 2023–2031 (USD MILLION) 203.
TABLE 239 HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2031 (USD MILLION) 204.
TABLE 240 NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 204.
TABLE 241 EUROPE: HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 204.
TABLE 242 ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 205.
TABLE 243 LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 205.
TABLE 244 HUMAN ORGANOIDS MARKET, BY REGION, 2023–2031 (USD MILLION) 207.
TABLE 245 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 208.
TABLE 246 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY OFFERING,.
2023–2031 (USD MILLION) 209.
TABLE 247 NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,.
2023–2031 (USD MILLION) 209.
TABLE 248 NORTH AMERICA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION) 209.
TABLE 249 NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,.
2023–2031 (USD MILLION) 210.
TABLE 250 NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION) 210.
TABLE 251 NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,.
2023–2031 (USD MILLION) 211.
TABLE 252 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,.
2023–2031 (USD MILLION) 211.
TABLE 253 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 212.
TABLE 254 NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY END USER,.
2023–2031 (USD MILLION) 212.
TABLE 255 NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 213.
TABLE 256 US: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION) 213.
TABLE 257 US: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION) 214.
TABLE 258 US: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,.
2023–2031 (USD MILLION) 214.
TABLE 259 US: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,.
2023–2031 (USD MILLION) 214.
TABLE 260 US: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,.
2023–2031 (USD MILLION) 215.
TABLE 261 US: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,.
2023–2031 (USD MILLION) 215.
TABLE 262 US: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION) 216.
TABLE 263 US: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 216.
TABLE 264 US: HUMAN ORGANOIDS MODELS MARKET, BY END USER,.
2023–2031 (USD MILLION) 217.
TABLE 265 US: HUMAN ORGANOID SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 217.
TABLE 266 CANADA: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION) 218.
TABLE 267 CANADA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,.
2023–2031 (USD MILLION) 218.
TABLE 268 CANADA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,.
2023–2031 (USD MILLION) 218.
TABLE 269 CANADA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,.
2023–2031 (USD MILLION) 219.
TABLE 270 CANADA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,.
2023–2031 (USD MILLION) 219.
TABLE 271 CANADA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,.
2023–2031 (USD MILLION) 220.
TABLE 272 CANADA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,.
2023–2031 (USD MILLION) 220.
TABLE 273 CANADA: HUMAN ORGANOIDS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 221.
TABLE 274 CANADA: HUMAN ORGANOIDS MODELS MARKET, BY END USER,.
2023–2031 (USD MILLION) 221.
TABLE 275 CANADA: HUMAN ORGANOID SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 222.
TABLE 276 EUROPE: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 222.
TABLE 277 EUROPE: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION) 223.
TABLE 278 EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,.
2023–2031 (USD MILLION) 223.
TABLE 279 EUROPE: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,.
2023–2031 (USD MILLION) 223.

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(バイオ薬物)の最新刊レポート

MarketsandMarkets社の Biotechnology分野 での最新刊レポート

本レポートと同じKEY WORD(source)の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2026/11/19 10:27

160.48 円

176.53 円

213.76 円

ページTOPに戻る